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ABSTRACT 
Understanding systemic biological pathways and the key cellular mechanisms that 
dictate disease states, drug response, and altered cellular function in metabolic disorders 
is a significant challenge. Research in the last 20 years have made it clear that tissue 
communication, through the actions of endocrine, paracrine or autocrine factors play a 
significant role in pathogenesis of complex multiorgan diseases such as the metabolic 
syndrome. The actions of these factors are governed both at the site of production and 
through mechanisms that regulate the sensitivity of target tissues. 
 
The Suppressors of Cytokine Signaling (SOCS) proteins act as negative regulators of 
the main cytokine and growth factor signaling pathways in multiple tissues and as such 
have important physiological functions. The molecular basis for SOCS actions as well 
as their role in the pathogenesis of metabolic diseases is just starting to be understood. 
All SOCS proteins (SOCS1 to 7 and CIS) are characterized by the presence of 
structural motifs called SOCS box and a SH2 domain. SOCS are thought to act as 
substrate recognition subunits of multimeric Cullin/RING E3 ubiquitin ligase 
complexes. It has been proposed that the SH2 domain mediates the recognition of 
tyrosine phosphorylated signaling proteins to be targeted for ubiquitination and 
subsequently, proteasomal degradation, thereby inhibiting cytokine signaling.  
  
In this thesis we investigated the mechanisms of action of SOCS2 and SOCS6 in the 
inhibition of cellular signaling and the physiological consequence of their actions. We 
demonstrated that both SOCS2 and SOCS6 assemble a canonical ECS 
(Elongin/Cullin/SOCS) complex through the interaction of SOCS box with Elongin B 
and C, cullin 5 and Rbx2.  We also demonstrated that SOCS2 and SOCS6 exert E3-
ligase activity towards the growth hormone (GH) receptor and cKIT proteins, 
respectively. Our structural and binding studies confirmed the existence of substrate 
binding motifs mainly in the SH2 domains and the N-terminal domain of both SOCSs. 
The C-terminus harbours the cullin 5 recognition domain that controls both E3 ligase 
activity of the complex as well as the SOCS stability. We proposed that extended target 
recognition domain in the SOCS proteins may serve to broaden their specificity toward 
various targets and hence their ability to regulate various signaling pathways. On the 
other hand, the existence of a degradation signal within the Elongin C interacting 
domain of SOCS proteins may serve to secure their timely actions avoiding 
competition from SOCS that are not engaged in active E3 ubiquitin ligase complexes. 
 
The patho-physiological role of SOCS2 was studied in SOCS2 knockout (SOCS2-/-) 
mice. In line with the in vitro studies (paper I), we observed an increased GH 
sensitivity in SOCS2-/- mice, demonstrated by low plasma GH/IGF1 ratio. In the liver, 
this enhanced sensitivity was manifested through increased VLDL secretion and 
reduced hepatic triglycerides levels. SOCS2-/- showed reduced hepatic steatosis upon 
high fat feeding as compared to wild type littermates but also exhibited increased 
adiposity and fat deposition in the skeletal muscles accompanied by profound systemic 
insulin resistance. We also demonstrated the involvement of SOCS2 in the regulation 
of inflammatory pathways. SOCS2-/- mice showed an exacerbated response to a high 
fat diet, with increased expression of inflammatory cytokines such as IL-6, RANTES, 
IL1β both in the liver and adipose tissue.  We also identified possible mechanisms to 
explain these phenomena by demonstrating that macrophages isolated from SOCS2-/- 
mice showed higher phagocytic activity and higher LPS-induced NF-κB activity; 
indicative of SOCS2 negative regulation of TLR4 signals.  
 
Given the short half-life of SOCS proteins in the cells, the regulation of SOCS gene 
transcription is an important mechanism to control their function. The nuclear receptor 
LXR has regulatory functions on hepatic lipid metabolism that overlap with those 
controlled by the GH. Therefore, in order to understand the molecular basis for possible 
crosstalks between these two pathways, we studies how LXR ligands regulate the GH 
receptor signaling in liver. We showed that LXR agonist downregulates STAT5b 
protein levels and suppresses GH receptor activity in hepatocytes through a mechanism 
involving SREBP1. The regulation by SREBP1 occurs through the modulation of 
STAT5b protein stability and results in reduced expression of GH target genes such as 
SOCS2. These results provide a plausible explanation for the hepatosteatosis observed 
upon LXR agonist treatment in vivo. 
  
In conclusion, through structural, in vivo and in vitro studies, we provide mechanistic 
and functional data on SOCS2 and SOCS6; information that may lead to a better 
understanding of the distinct physiological functions of these proteins. Given our 
demonstration on the key role of ubiquitination on SOCS functions, future mechanistic 
studies of SOCS2 and SOCS6 function should focus on the identification of 
ubiquitination targets of these proteins. Are the physiological functions ascribed to 
these proteins a result of the degradation of a few target proteins or do they have many 
targets? If the later is the case, how is SOCS target-specificity structurally determined 
and how is their activity regulated in time and cellular location? The demonstration that 
SOCS2 regulate both GH receptor and TLR4 signaling offers system where these 
questions can be addressed. At physiological levels, the SOCS2-/- mice constitute a 
novel model system for the study of the metabolic syndrome with unique features that 
are relevant to the human disease. In the SOCS2-/- mice, insulin resistance and 
production of inflammatory cytokine are exacerbated by high fat feeding and associated 
with obesity and deposition of triacylglycerides in the muscle. In these conditions 
reduced accumulation of TG in liver is observed. This model presents opportunities for 
future investigations aiming to distinguish between steatotic versus inflammatory 
causes for insulin resistance. 
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1 INTRODUCTION 
Fatty liver disease also known as hepatic steatosis is a pathological condition 
characterized by the retention of lipids in the hepatocytes exceeding 5% of the liver 
weight1 that may result from impairment in the synthesis or mobilization of 
triacylglycerides (TAG)2. Fatty liver disease is classically divided into alcoholic fatty 
liver disease in individuals with ethanol intake >20g/day and non-alcoholic fatty liver 
disease (NAFLD) 3. 
 
Patients with NAFLD are usually asymptomatic although fatigue and upper abdominal 
discomforts are commonly reported4. The prevalence of NAFLD in the general 
population is estimated to be 20–30% in the Western countries 2 and it is more frequent 
among individuals with type 2 diabetes (50%) and obesity (76%) 5, 6. The histological 
spectrum of NAFLD spans from simple steatosis to hepatocellular inflammation with 
cellular damage (nonalcoholic steatohepatitis, or NASH) that may be further 
complicated to fibrosis and can ultimately progress to cirrhosis. The extent and pattern 
of fat deposition in the hepatocytes further subdivides hepatic steatosis into 
microvesicular and macrovesicular steatosis 7. In the latter case, the fat vacuoles are 
large enough to displace the cytoplasm and push the nucleus to the periphery. This 
histological classification provides an indication about the duration of lipid 
accumulation (chronic or acute) and also about the etiopathogenesis. The most common 
form of NAFLD is primarily caused by mediators of metabolic syndrome, such as 
insulin resistance and obesity. Secondary causes of NAFLD are listed in Table 1 and 
reviewed elsewhere 2, 8. 
 
NAFLD is clinically important since it occurs frequently in the general population and 
it may potentially progress to become an advanced hepatic and extrahepatic disorder. 
Identification and understanding of the predisposing factors leading to NAFLD gives 
better prognostic information in an individual patient 9. Due to the high risk for 
development of NAFLD-related complications, the mortality rate for patients with 
NAFLD is higher than for age and sex-matched controls 10, 11.  Retrospective studies 
indicate that 38% of patients with NAFLD with histological necroinflammation 
progress to liver fibrosis 12 and 30-70% of patients with cryptogenic cirrhosis had end-
stage NASH 9. Furthermore, 13% of hepatocellular carcinoma cases were attributed to 
NASH-related cirrhosis 13. NAFLD is also known to occur after normal liver transplant 
surgery to patients with NASH 14. Taken together, these statistics show the importance 
to further study the molecular basis of NAFLD.  
 
 
1.1 PATHOGENESIS OF NAFLD AND NASH: 
Mechanisms that govern the progression of simple hepatic steatosis to NASH are 
multifactorial. The two-hit hypothesis has been suggested by Day and James15 to 
explain how this process occurs.  Accumulation of hepatic lipids, caused by changes in 
uptake, synthesis, and secretion of lipids, constitutes for the first insult. A variety of 
factors have been implicated as the second “hit” driving the progression to NASH. 
These include the actions of inflammatory cytokines, oxidative stress, mitochondrial 
dysfunction and gut-derived bacterial endotoxins 15, 16.  The two-hit hypothesis suggests 
that TAG accumulation acts as an inert bystander. Hence, an alternative hypothesis was 
presented first by Heribert Thaler that considers the central role of lipotoxicity from 
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TAG and fatty acid metabolites in the hepatocellular injury observed in NAFLD 17, 18.  
Figure 1.1 summarizes the contributing factors involved in the development of NALFD 
and NASH and these will be discussed further in this chapter. 
 
Table 1: Secondary factors contributing to the development of non-alcoholic 
fatty liver disease 
Genetic/metabolic 
Wilson’s disease 
Lipodystrophy 
Cholesterol ester storage disease 
Hemochromatosis 
Reye’s Syndrome 
Hypobetalipoproteinemia 
Wolman’s disease 
 
Drug induced 
Glucocorticoids 
Estrogen 
NSAID’S 
Methotrexate 
Hypervitaminosis A 
Tamoxifen 
Calcium antagonists 
Anti-retroviral drugs 
Tetracycline 
Nutritional 
Total parental nutrition 
Intestinal bypass 
Rapid weight loss 
Prolonged starvation 
High carbohydrate diet 
Protein malnutrition 
Toxins 
Toxic mushrooms 
Petrochemicals 
Phosphorus 
Extrahepatic causes 
Cardiac failure 
Irritable bowl syndrome 
Infected diverticulosis 
Hypothyroidism  
GH deficiency 
Pregnancy 
Polycystic ovarian syndrome 
Infection 
Hepatitis C 
Hepatitis B 
Intestinal bacterial growth 
 	  
1.1.1 Factors enhancing lipid delivery to the liver 
Non-alcoholic fatty liver disease is a multifactorial disorder linked to 
hypertriglyceridemia, insulin resistance and obesity. The primary cause of hepatic 
steatosis is an elevated supply of fatty acids to the liver, either from nutritional sources, 
excessive adipose tissue lipolysis, defective lipid mobilization or increased hepatic de 
novo lipogenesis (DNL). The relative importance of these factors depends on their 
primary cause. For example, rapid weight loss as well as obesity is related to the 
development of fatty liver, in the first cases it is due to increased lipolysis in adipose 
tissue while in obesity, the dietary intake has a prominent role.  
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Figure	   1.1:	   The	   two	   hit	   theory	   of	   the	   development	   of	   non-­‐alcoholic	   steatohepatitis	   (NASH).	  Factors	  involved	  in	  the	  development	  of	  the	  first	  hit	  (blue)	  include	  enhanced	  fatty	  acid	  delivery	  to	  the	  liver,	  enhanced	  de	  novo	  lipogenesis	  and	  impaired	  disposal	  of	  triacylglycerides	  (TAG).	  Factors	  involved	  in	  the	  development	  of	  the	  second	  hit	  are	  in	  red.	  Further	  details	  are	  in	  the	  text.	  
 
1.1.1.1 Nutritional factors 
Diet plays a critical role in the development of NAFLD in humans. Fatty liver is the 
most common histological finding in patients receiving total parenteral nutrition (TPN) 
19. TPN increases the load of glucose, lipid or total calories and leads to fat 
accumulation in the liver20. Other nutritional factors include an imbalanced diet of high 
carbohydrate consumption, which in excess get converted into fat and predispose to 
obesity and insulin resistance 21. Collectively, an increased dietary supply of calories 
enhances the delivery of fat or the synthesis in the liver. NAFLD is also observed in 
extreme malnutrition. Kwashiorkor, a form of severe protein deficiency, is associated 
with fatty liver most likely due to the accompanied insulin resistance22. Deficiencies in 
both carnitine, involved in fat oxidation, and choline, involved in VLDL assembly, as a 
result of malnutrition or post-TPN have been associated with NAFLD 23,24. 
Gastrointestinal bariatric bypass surgical procedures causes profound fasting, protein 
calorie malnutrition and rapid weight loss which increases the flux of free fatty acids 
into the liver, which even in short term may cause deterioration of liver functions 25. 
However, these effects are transient in which numerous observational studies have 
demonstrated that bariatric surgery may cause regression of NAFLD in line with 
improved whole body insulin sensitivity and enhanced mitochondrial function 25, 26.  
 
In rodents, methionine-choline deficient (MCD) diet impairs VLDL secretion due to 
inhibition of phosphatidyl choline synthesis and can induce fatty liver within 2-4 weeks 
of feeding 27. However, rodents fed with this diet do not develop obesity and insulin 
resistance in contrast to what is observed in humans with NASH and other diet-induced 
NAFLD28, 29. On the other hand, the choline-deficient diet induces dyslipidemia, insulin 
resistance and results in a less severe fat accumulation, inflammation and necrosis in 
the liver when compared to methionine-choline deficient diet 30, 31. High fat diet (HFD) 
is also well known to induce obesity and insulin resistance in rodents. It increases 
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hepatic lipid content quite rapidly, before a significant increase in fat accumulation in 
the peripheral tissues is observed. However, HFD in rats induces a milder steatosis 
when compared to the methionine-choline deficient diet and the rats show fewer signs 
of inflammation and fibrosis 32, 33.  
 
1.1.1.2 Increased peripheral lipolysis 
The sources of hepatic free fatty acids are primarily adipocyte triacylglyceride lipolysis 
and hepatocyte de novo lipogenesis (DNL). In normal individuals, fasting DNL 
contributes to about 5% of the total free fatty acids (FFA) but it increases up to 26% in 
patients with NAFLD 34, 35. Other minor contributors include the uptake of short chain 
fatty acids delivered through portal circulation and lysosomal breakdown of lipoprotein 
remnants and autophagosomes, containing limited TAG34. The liver lipoprotein lipase 
(LPL) is normally not expressed in adults but its expression increases as a response to 
infection, cancer cachexia and cytokine stimulation 36. Liver specific expression of LPL 
increases hepatic uptake and accumulation of TAG 37. Circulating triacylglycerides are 
not a direct source of fat for the liver and therefore pharmacological reduction of serum 
TAG levels might not have a significant direct beneficial effects on the liver 34. 
 
Peripheral lipolysis is regulated by hormonal, neural and pharmacological stimuli that 
releases FFA into the circulation and later deposits them in the liver and skeletal 
muscles. Table 2 summarizes the factors that regulate adipocyte lipolysis (reviewed in 
ref. 38). Genetic mouse models of high plasma FFA levels such as CD36 knockout mice 
and muscle specific deletion of LPL develops hepatosteatosis due to increased FFA 
flux to the liver 39, 40.  It is worth to mention that the impact of increased peripheral 
lipolysis associated with prolonged starvation or insulin resistance on the liver is 
modulated by the oxidative capacity of the muscle. Muscle specific lipoprotein lipase 
(LPL) knockout mouse models are spared from the deleterious effect of high plasma 
FFA on the muscle but show severe hepatic steatosis39. Similarly, the SJL/J mouse 
strain tolerates fasting induced hepatic steatosis because of the enhanced compensatory 
muscle fat oxidation41.  This collectively emphasizes the role of enhancing peripheral 
fatty acid oxidation through exercise in the therapeutic management of NAFLD.   
 
1.1.2 Increased hepatic de novo lipogenesis  
Hepatic de novo lipogenesis refers to the process where excess glucose is converted to 
fatty acids. Enhanced DNL, has been demonstrated in both humans and murine models 
of steatosis 42. Sterol regulatory element-binding protein-1c (SREBP-1c) is a key 
transcription factor that mediates insulin stimulation of hepatic lipid synthesis 43. 
Similarly, elevated glucose levels also activates DNL via the carbohydrate response 
element-binding protein (ChREBP) 44. ChREBP, triggered by high plasma insulin or 
glucose, enhances the expression of liver pyruvate kinase, a key regulatory enzyme in 
glycolysis. A third transcription factor that participates in the development of hepatic 
steatosis in rodents is PPAR-γ. In human, hepatic PPARγ expression is very low 
compared to rodents 45, 46. In animal models, hepatic expression of PPARγ is low but 
significantly increases in conditions of insulin resistance and fatty liver 47. Hepatic 
knockout of PPAR-γ in livers of obese mice markedly attenuates the development of 
hepatic steatosis, independent of the presence of hyperinsulinemia or hyperglycemia 48; 
while viral mediated hepatic overexpression of PPARγ in mice leads to hepatic 
steatosis with upregulation of a wide range of PPARγ-responsive genes. PPARγ exerts 
other functions, especially those relevant to the development of NASH. PPARγ shows 
antifibrogenic actions in which it reverses the activation of hepatic stellate cells toward 
a resting state 49, 50.  
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Table 2: Factors that regulates adipose tissue lipolysis  
Effect on lipolysis Mechanism 
Decrease lipolysis  
Insulin Activates Akt , lowers cAMP and inhibits HSL 
PPARγ Promotes lipid droplet formation and stabilization 
Adipocyte PLA2 Releases arachidonic acid for PGE2 synthesis 
Increase lipolysis  
Catecholamines Enhances camp through adrenergic receptors 
Glucagon Enhances cAMP 
Growth Hormone Enhances HSL activity 
ACTH Enhances cAMP 
Methylxanthines Enhances cAMP and releases catecholamines 
Adipocyte triacylglyceride lipase 
(ATGL or PNPLA2) Hydrolysis of TAG 
Adiponutrin (PNPLA3) Hydrolysis of TAG 
HSL Hydrolysis of TAG 
Perilipins Activates ATGL 
TNFα Activates JNK and induces insulin resistance 
JNK Serine phosphorylation of insulin receptor substrate-1 ACTH,	   adrenocorticotropic	   hormone;	   cAMP,	   cyclic	   adenosine	   monophosphate;	   HSL,	   hormone	  sensitive	  lipase;	  PPAR,	  peroxisomal	  proliferator	  activated	  receptor;	  JNK,	  c-­‐Jun	  N-­‐terminal	  kinase	  
 
 
1.1.3 Impaired disposal of hepatic triacylglycerides 
1.1.3.1 Decreased oxidative capacity 
Fatty acids are oxidized to carbon dioxide and water through β-oxidation 
(mitochondrial and peroxisomal) and ω-oxidation (endoplasmic reticulum). All these 
oxidative pathways are strongly regulated by the PPARα nuclear receptor 51. PPARα 
serves as a sensor for a broad array of lipophilic species and it heterodimerize with the 
retinoid X receptor to induce genes that regulate fatty acid oxidation 51. On the other 
hand, the nuclear receptor PPARγ, which also senses lipophilic species, promotes the 
formation and export or storage of fatty acids as triacylglycerides. 
 
The shuttling of FFA for either oxidation or formation of TAG is tightly controlled. In 
the liver, β-oxidation is inhibited in the fed state as a result of insulin actions. Cellular 
levels of malonyl-CoA and ATP are potent inhibitors of β-oxidation. Deletion of the 
ACC2 gene or Adenoviral-mediated expression of malonyl-CoA decarboxylase in mice 
lowers the cellular levels of malonyl-CoA which in turn enhances β-oxidation and 
therefore these mouse models are protected from diet-induced NAFLD 52, 53. Animal 
models of reduced oxidative capacity includes the carnitine deficient mouse, i.e. 
juvenile visceral steatosis (JVS), that develop severe hepatic steatosis within days after 
birth 54.  
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Mitochondrial dysfunction, genetic or acquired, is a well-known observation in patients 
with NASH 55  Peroxisomal β-oxidation can take over when the mitochondrial 
oxidation is dysfunctional. Acyl-CoA oxidase (AOX) catalyzes the first step of 
peroxisomal β-oxidation. Substrates of AOX include very long chain fatty acids, 
arachidonic acid metabolites, leukotriene B4, and 8(S)-hydroxyeicosatetraenoic acid. 
Inhibition of peroxisomal β-oxidation leads to NASH and stimulation of peroxisomes 
by PPARα agonists protects againsts NASH 56-58. The AOX deficiency disease 
(pseudoneonatal adrenoleukodystrophy) manifests in the neonatal period with 
hypotonia and children die between ages 4-5 years 59. AOX knockout mice show 
defects in peroxisomal β-oxidation with severe age-progressive hepatic steatosis 29.   
 
Microsomal ω-oxidation via the smooth endoplasmic reticulum cytochrome P450 
(CYP) oxidizes a variety of lipid compounds including the FFA. Upregulation of 
various CYP isoforms, e.g. CYP4A11, have been reported in patients with NASH 60. 
CYP enzymes catalyze the first step of ω-hydroxylation forming dicarboxylic acids 
which then are conjugated to CoA by the action of the microsomal acyl-CoA 
synthetase. Dicarboxylic acids can impair mitochondrial function by uncoupling 
oxidative-phosphorylation 61, 62. Yet, the importance of microsomal oxidation in the 
progression to NASH has not been confirmed.  
 
Triacylglyceride in tissue are hydrolyzed under the action of lipases. In adipose tissues, 
TAG is hydrolyzed by adipose triacylglyceride lipase (ATGL or desnutrin) and DAG is 
hydrolyzed by HSL 63. In the liver, the expression levels of ATGL are much lower 
compared to adipose tissue 63. Mice with ATGL deletion display higher adipose tissue 
mass and knockdown of liver-ATGL causes steatosis 64. PNPLA3 or adiponutrin is 
another TAG lipase predominantly expressed in the adipose tissue and liver. It has very 
high homology with ATGL and it is involved the re-esterification of TAG in the 
hepatocytes 64, 65. The hepatic expression of PNPLA3 in mice is upregulated by high fat 
feeding and fasting downregulates its expression 66. This suggests that PNPLA3 has 
important function in the hepatic lipid mobilization. Indeed, point mutations in 
PNPLA3 genes are strongly associated with NAFLD in children and adults 67, 68.  
 
1.1.3.2 Decreased TAG assembly and secretion 
 
Hepatic export of TAG, as very low-density lipoprotein (VLDL), is accomplished by a 
regulated protein machinery. Studies on livers from patients with NASH showed 
disturbed VLDL metabolism and secretion69. The rate-limiting step of VLDL assembly 
is controlled by the microsomal TAG transfer protein (MTTP), located in the 
endoplasmic reticulum. Mutations in this protein in human are responsible for the 
autosomal recessive condition abetalipoproteinemia, which is characterized by severe 
hepatic steatosis and cirrhosis70, 71. Several commonly used drugs (e.g. doxycycline and 
tetracycline) are known to affect β-oxidation and inhibit MTTP activity in animal 
models of drug-induced steatosis 72.   
 
1.1.4 Progression of hepatic steatosis to NASH. Introducing the 2nd hit 
Extensive studies have been carried out to understand the mechanisms of how 
intrahepatic lipid accumulation progresses to the development of inflammation and 
fibrosis.  One third of patients with hepatic steatosis are estimated to progress to 
steatohepatitis 73. NASH is characterized by cumulative defects in cellular organelles 
(e.g. mitochondria), elevated systemic and local levels of cytokines and recruitment of 
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inflammatory cells. Fatty acid accumulation results in increased generation of reactive 
oxygen species (ROS), induction of cellular stress responses [e.g., activation of protein 
kinase C (PKC), mitogen-activated protein kinase (MAPK), Jun N-terminal kinase 
(JNK), nuclear factor-κB (NF- κB)], and subsequent expression of pro-inflammatory 
cytokines, such as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6) 74. These 
cytokines are involved in the activation of Kupffer cells and also the transformation of 
stellate cells to a fibromyoblastic cell type, contributing to the progression from 
steatosis to steatohepatitis 75. In this section we will further discuss the molecular basis 
of lipid toxicity and the development of inflammation.  
  
1.1.4.1 Lipotoxicity 
 
Lipotoxicity describes cellular injury and death caused by free fatty acids, their 
metabolites, and even by lipid droplets and triacylglycerides, although the later two are 
found to be generally inert.  
 
Triacylglycerides: TAG accumulation is associated with tissue injury and insulin 
resistance in the muscle and liver 76. However, current data suggest that this association 
lacks causality.  Diacylglycerol acyltransferase 2 (DGAT2) catalyzes the last step of 
TAG synthesis. In mice, overexpression of DGAT2 leads to hepatic TAG accumulation 
and endoplasmic reticulum (ER) stress, shown by the enhanced phosphorylation of 
PERK (protein kinase R-like endoplasmic reticulum kinase) 77. However, the 
accumulated TAG did no increase the activity of proinflammatory pathways such as 
JNK and NF-κB 77. In contrast, blocking of DGAT2 causes lower hepatic TAG 
accumulation but increased FFA levels resulting in lipotoxic cell injury 78. Furthermore, 
cellular injuries or inflammatory responses were not observed after TAG accumulation 
caused by blocking the MTTP-mediated TAG incorporation to VLDL 79. In β−cells, 
overexpression of perilipin increases TAG accumulation and protects against palmitate-
induced suppression of glucose mediated insulin secretion 80.  Overall, these studies do 
not support a direct role of TAG in lipid mediated liver injury but do not exclude that 
the stored TAG could serve as a source of other lipotoxic intermediates.  
 
Other studies have suggested that lipid droplets by themselves have metabolic actions 
in regulating cellular signaling; in particular those that regulate lipid storage and 
disposal. Lipid droplets construct a continuous intracellular membrane system 
(membrane flow hypothesis) that enables exchanges between lipid droplet and lipid 
mobilizing organelles such as peroxisomes and mitochondria 81. Studies have 
confirmed the role of lipid droplets in the regulation of lipid oxidation 81, 82. Reduction 
of adipophilin, a component of lipid droplets, leads to enhanced expression of lipogenic 
genes in mouse models of NAFLD 83. The close proximity between lipid droplet and 
these organelles regulates the substrate availability for oxidation. In fact, studies on 
yeast shown that some lipid droplets contain extension of peroxisome and hence named 
as pexopodia 81.   
 
 
Free fatty acids: FFA has deleterious effects on biological systems and hence is found 
bound to proteins such as albumin in circulation and fatty acid binding proteins (FABP) 
inside the cells. Studies on mice show that knockout of liver-FABP can block TAG 
accumulation after treatment with a MTTP inhibitor 84, 85. The net flux of FFA into the 
liver is relatively more important than the actual concentration for the development of 
NASH 34. Cellular concentrations of FFA in the liver remain fairly constant despite the 
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increase in circulating levels in patients with NASH 86. In the cells, FFA can induce 
cellular damage by activating inflammatory and apoptotic pathways, some of which 
can be initiated by vinding of saturated fatty acids to Toll-like receptor 4 (TLR4) 87. 
Furthermore, FFAs induce the translocation of the proapoptotic Bax protein to the 
lysosome and subsequently enhances lysosome permeability and the release of 
cathepsin B which initiates the cellular death program, (Figure 1.2) 88. Beside 
mitochondrial dysfunction, cathepsin B induces NF-kB activity and subsequent TNFα 
expression88. FFAs also serve as ligands for PPARγ and PPARα to regulate storage or 
disposal of lipids89. Additional cytotoxic effects of FFA occur via the formation of 
acyl-CoA90. Inhibition of FFA esterification with CoA by triacsin C significantly 
blockes palmitate induced pancreatic β-cell deaths 90. In hepatocytes, triacsin C 
treatment also blockes the palmitate-induced inhibition of insulin signaling. All 
together, these data suggest that palmitoyl CoA ester formation is critical in mediating 
the cytotoxic effects of FFA91. 
 
Ceramides: Ceramides are mainly found in the plasma membrane and are composed 
of sphingosine and fatty acids. They serve as cellular signals for proliferation, 
differentiation and apoptosis, most importantly activation of protein kinase Cθ  leading 
to an inhibitory serine/threonine phosphorylation of IRS1 and 2 92, 93. Cellular levels of 
ceramide are increased in livers of patients with NASH 94. However, blocking the 
ceramide synthesis does not abolish the palmitate-induced steatohepatitis 92, 93. Further 
studies are required to determine the importance of ceramides in the development of 
NASH. 
  
Diacylglycerol (DAG): DAG acts as an important second messenger that modulates 
the function of several signaling proteins. The plasma membrane levels of DAG 
increase upon stimulation of a multitude of cellular signaling pathways. DAG is 
primarily synthesized by the action of PI2-specific phospholipase C isoenzymes, which 
are activated by G-coupled protein receptors, Ca2+, protein receptor tyrosine kinases 
and Ras. Phospholipase C produces DAG and PI3, which in turn lead to Ca2+ 
mobilization and further activation of the DAG synthesis and downstream signaling.. 
DAG, in synergy with Ca2+, binds to and regulates the function of various downstream 
signaling molecules in particular protein kinase C (PKC), a serine/threonine kinase. 
PKC activates JNK, ERK and NF-κB which all activate the transcription of 
inflammatory cytokines 95. DAG has been proposed to contribute in the progression of 
NAFLD. Serine/threonine activity of PKC induces insulin resistance and indeed the 
content of DAG and its activation of PKCε are found to be the best predictor of hepatic 
insulin resistance in human liver samples 96. Although the hepatic cellular levels of 
DAG are found to be high in biopsy samples obtained from patients with NASH 86, 97, 
no differences are observed when comparing to simple steatosis 86.  
 
Lysophosphatidyl choline: phosphatidyl choline or lecithin is synthesized from DAG 
and it is a major component of plasma membrane, lipid droplet, and VLDL particles. 
Lysophosphatidyl choline (LPC) is formed from lecithin under the action of 
phospholipase A2. Hepatocytes may undergo steatosis if the DAG→TAG pathway 
prevails or may enter apoptosis if the DAG→PC→LPC pathway predominates 93. The 
balance of these two pathways might depend on a “second hit,” such as inflammatory 
cytokines 93. LPC is known to cause direct cellular injury and stimulation of immune 
cells, thus mediates the progression to NASH 98. Similar to DAG, LPC also activates 
PKC in cells and induces apoptosis 93, 99. Unlike DAG’s inhibition, the inhibition of 
LPC synthesis blockes the palmitate-induced apoptosis in cultured and primary human 
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hepatocytes 93. Studies have shown that LPC impairs mitochondrial permeability and 
causes the release of cytochrome c, which ultimately activates caspase reaction and 
initiates apoptosis 93, Figure 1.2. LPC is also known to activate JNK and subsequently 
enhance proinflammatory pathways 93, 100.  
 
 
Figure 1.2: Cellular apoptotic pathway. Mitochondrial damage and increased membrane permeability 
causes release of cytochrome c that activates the caspase pathway which ultimately activates apoptotic 
cell damage pathways. Mitochondrial damage is achieved by binding to Bid, BAX and cathepsin B 
molecules. BAX is activated by proinflammatory signals from circulating cytokines or by the lysosomes. 
Free fatty acids (FFA), reactive oxygen species (ROS) and hypoxia induced by hepatic steatosis 
introduces damage to lysosomes and mitochondria and activate endoplasmic reticulum stress. 
 
1.1.4.2 Oxidative stress and mitochondrial dysfunction 
 
Oxidative stress has been implicated as an etiological factor in many progressive liver 
diseases including alcoholic steatohepatitis, Wilson’s disease, hepatitis C and toxin 
induced liver failure. Reactive oxygen species (ROS), including superoxide (O2-), 
hydrogen peroxide (H2O2), and hydroxyl radical (OH.), and reactive nitrogen species, 
including nitric oxide (NO) and peroxynitrite (ONOO-) are physiologically generated in 
normal hepatocytes and at low concentrations are critical for normal physiological 
processes, including oxidative respiration, apoptosis, and microsomal defense pathways 
101. In macrophages or Kupffer cells, ROS are also generated by the action of NADPH 
oxidase and myeloperoxidase101. ROS cellular toxicity encompasses their interaction 
with cellular macromolecules, denaturing or inactivating enzymes and causing DNA 
damage.   
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Lipid peroxidation can lead to the destruction of biological membranes and to 
production of reactive aldehydic products such as malondialdehyde or 4-
hydroxynonenal. These lipid hydroperoxides have longer half lives than ROS and 
diffuse more to introduce damage to distant intracellular organelles and extracellularly 
102. Mechanisms by which these hydroperoxides potentiate development of NASH 
include ER stress, mitochondrial dysfunction, glutathione depletion, and the attenuation 
of VLDL secretion 103. These products can also directly activate hepatic stellate cells 
and are chemotactic for neutrophils inducing further hepatocyte necrosis, inflammation, 
and liver fibrosis  
 
ROS are direct cause of mitochondrial dysfunction due to their interference with 
oxidative phosphorylation and damage of the mitochondrial DNA 104. Mitochondrial 
dysfunction blocks the normal electron flow for the reduction of oxygen to water. This 
will results in the transfer of free electrons to oxygen or lipids enhancing the generation 
of ROS.  
 
Mitochondrial dysfunction in NASH pathogenesis may also result from the action of 
inflammatory cytokines. TNFα, produced by Kupffer cells, hepatocytes or adipocytes, 
activates Bax translocation to the mitochondria, which enhances the permeability of the 
outer membrane and blocks the electron flow105, Figure 1.2. In addition, TNFα 
activates caspase 8 which enhances the release of cathepsin B from the lysosomes. 
Cathepsin B acts on the mitochondria and increases their membrane permeability and 
blocks the electron flow by releasing cytochrome c 106, Figure 1.2. The enhanced ROS 
production further leads to damage of mitochondrial DNA, membranes and proteins 101. 
Collectively, enhanced mitochondrial permeability and cytochrome c release leads to 
the release of caspase 3 which later initiates cellular processes of apoptosis106. 
Apoptosis then further stimulates Kupffer cells activity and thus generates a vicious 
cycle. Oxidative stress is also known to promote the proliferation of stellate cells, and 
expression of adhesion molecules, which promote infiltration of immune cells 107, 108. It 
is noteworthy that serum levels of ICAM-1, an adhesion molecule, are significantly 
elevated in patients with NASH 109.  
 
Excessive ROS production is normally counteracted by enzymatic and non-enzymatic 
antioxidants. These enzymes include: superoxide dismutase, catalase, and glutathione 
(GSH) peroxidase. Another adaptive mechanism is the increased expression of 
uncoupling protein-2 (UCP-2) which reduces the cellular levels of ROS104, 110. 
Uncoupling of oxidative phosphorylation by UCP-2 allows the backflow of H+ to the 
mitochondrial matrix and thereby oxygen tension is reduced. Upregulation of hepatic 
UCP-2 has been confirmed in liver biopsies from NASH patients110. However, this 
adaptive response may increase the hepatic susceptibility to other stressors such as 
hypoxia, TNFα- and drug-induced toxicity 104, 110, 111. Hypoxia may result from 
impaired microcirculation observed in severe steatosis and this may further increase 
liver injury 112. 
 
Non-enzymatic antioxidants include GSH, Vitamin E and C, and ubiquinone101. GSH, 
an endogenous antioxidant, is present at high concentrations in hepatocytes and 
mitochondria which helps to eliminates reactive molecules generated during oxidative 
stress113. Thus, the balance between oxidative stress and GSH levels may influence the 
development of NASH. Yet, the depletion of hepatic glutathione has not been reliably 
shown to occur in NASH 113. However, treatment with antioxidants, e.g., vitamin E, β-
carotene, and n-3 polyunsaturated fatty acids (PUFAs), alleviates hepatic steatosis and 
the extent of liver injury in humans and animal models 114, 115.  
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1.1.4.3 Proinflammatory cytokines 
 
Together with the hepatocyte damage and fibrosis, inflammation is a marker of 
progression from simple steatosis to steatohepatitis and a great potential target for 
therapeutics. Inflammation in the liver results from the cross talk between parenchymal 
and nonparenchymal cells through circulating and paracrine cytokines. These cytokines 
are involved in the activation of hepatocytes, Kupffer cells and the transformation of 
stellate cells to the fibromyoblastic cell types75. Furthermore, pro-inflammatory 
cytokines and adipocytokines have been shown to play a role in the pathogenesis of 
NAFLD by modulating insulin resistance and lipid oxidation 101, 116. Plasma 
adiponectin and resistin levels are negatively correlated with hepatic steatosis and 
inflammation in NASH 117. TNFα is positively correlated with ongoing liver damage 
and inflammation 118.  Treatment with TNFα leads to functional and morphologic 
alterations in mitochondria while treatment with anti-TNFα antibodies improved 
mitochondrial function, inflammation, and alleviated hepatic steatosis in mouse models 
of NASH 119, 120. Proinflammatory cytokines also induce gene expression and secretion 
of chemokines, which attract and activate other immune cells. These cells include T-
cells and natural killer cells that upon activations cause cytotoxic damage. In the non-
inflamed human liver, several chemokines, including the regulated on activation, 
normal T cell expressed and secreted chemokine (RANTES), monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1) and 
IL-8, can be detected in vascular endothelium of portal tracts and their expressions 
increase markedly with inflammation 121, 122. 
 
TNFα and IL-6 activate specific intracellular pathways that can enhance peripheral 
lipolysis and mitochondrial dysfunction. NF-κB homodimers and heterodimers are 
generated by association of five members of the Rel family that become activated upon 
assembly of a kinase complex formed by two catalytic subunits, IKK1 (IKKα) and 
IKK2 (IKKβ), and a regulatory subunit, IKKγ (NEMO) 123. The IKK kinase complex 
phosphorylates a group of inhibitory proteins, named IκB, leading to their degradation 
through the ubiquitin–proteasome pathway124. The NF-kB dimers migrate to the 
nucleus and regulate gene transcription. NF-κB pathway is activated in the livers of 
rodent models and in patients with NASH123. Experimental activation of NF-κB is 
sufficient to induce low-grade inflammation and insulin resistance 125. On the other 
hand, inhibition of IKKβ enhances insulin sensitivity 126. The other inflammatory signal 
mediator is JNK which belongs to a family of intracellular mitogen activated protein 
(MAP) kinases. JNK mediates phosphorylation and inactivation of Bcl-2 and promotes 
apoptosis. In fat-induced cell toxicity, JNK also leads to Bax activation and initiation of 
apoptosis 127, Figure 1.2. TNFα can activate JNK directly, early activation, or indirectly 
and persistently by TNFα-induced ROS in the late persistent phase128. The persistant 
activation of JNK by TNFα may contribute to the liver damage128. Further evidence for 
the role of JNK in NASH development comes from studies on JNK1 null mice. 
Methionine-choline defiecient (MCD) diet-fed JNK1 null mice have significantly lower 
hepatic TAG accumulation, inflammation, CYP2E1 expression, lipid peroxidation, 
liver injury, and apoptosis compared to the wild-type littermates 129.  
 
Toll-like receptors (TLR) are pattern recognition receptors that recognize microbial 
pathogens leading to the activation of innate immune system. Liver tissue from TLR4 
knockout mice showed absence of inflammatory gene expression after high fat feeding 
130. This supports the role of TLR4 in the pathogenesis of diet induced NASH. In 
Kupffer cells, medium chain fatty acids activate TLR4 signaling, whereas the 
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polyunsaturated fatty acids and docosahexaenoic acid inhibit activation of various 
TLRs 131. Palmitic acid activation of TLR4 triggers the activation of NF-κB and 
upregulation of its target genes TNFα, type I interferon, NO, IL-1 and IL-6 in 
leukocytes and Kupffer cells, all together contributing to the development of NASH 132.  
 
IL1β is another cytokine implicated in the development of NASH. IL1β is primarily 
produced by the Kupffer cells and its expression increases after TLR4 or TLR9 
activations 133. Deletions in mice of either TLR9 or its signaling mediator Myd88 
suppress the release of IL1β and produces phenotypes which resembles the one 
observed in mice lacking the IL1β receptor 133. All these mice models are protected 
from diet induced NASH development 133. Furthermore, treatment of hepatocytes with 
IL1β causes accumulation of TAG and induces cellular injury 133. In addition, IL1β 
also stimulates hepatic stellate cells and induces fibrogenesis.  
 
IFNγ in the liver is mainly produced by T-cells and exerts anti-proliferative and growth 
inhibitory actions on hepatocytes. IFNγ receptors are also present in Kupffer cells and 
stellate cells 134, 135. IFNγ has been shown in numerous reports to be anti-fibrogenic, 
both inhibiting the activation of hepatic stellate cells in culture and attenuating drug-
induced liver fibrosis136. IFNγ is currently being used in trials as an anti-fibrogenic 
therapeutic agent in patients with chronic liver disease 137, 138. However, studies on mice 
fed with a choline-deficient diet demonstrated that liver fibrosis is enhanced when mice 
were treated with IFNγ and reduced in IFNγ-deficient mice 139, 140. This finding is 
crucially important when applying IFNγ as a therapeutic target. 
 
IL6 is generally elevated in conditions of NASH, insulin resistance and obesity. IL-6 in 
circulation is produced by adipose tissue, skeletal muscle and liver parenchymal and 
Kupffer cells 141. Presently, the role of IL-6 in insulin resistance is unclear and still the 
subject of debate 141. Long-term administration of IL-6 to lean rodents causes hepatic 
insulin resistance in mice but increases whole body insulin sensitivity and glucose 
tolerance in rats142, 143. Overexpression of IL-6 in mice causes a pronounced 
proinflammatory state but does not cause hepatic steatosis 144.	  In mice, IL-6 deficiency 
causes insulin resistance and obesity. However, when fed with high fat diet these mice 
showed no differences in insulin sensitivity and adiposity when compared to the wild 
type littermates but developed exacerbated HFD-induced hepatic insulin resistance and 
inflammation 145,146, 147. Similarly, deletion of the liver IL-6/gp130-STAT3 axis leads to 
hepatic steatosis and inflammation 148.	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1.1.5 Role of non-parenchymal cells in development of NASH 
Hepatocytes constitute the largest proportion of liver mass. Sinusoidal structures are 
lined with endothelial cells and the hepatic resident macrophages, know as Kupffer 
cells (KC). KC constitute 5% of liver cells and 31% of the non-parenchymal 
subpopulation of cells149. The biliary canaliculi are formed by cholangiocytes and 
stellate cells of mesenchymal origin, and it lies scattered in the space of Disse, Figure 
1.3. Cross talk and exchange of proinflammatory cytokines between these cells is 
thought to contribute to the pathogenesis of NASH. Other circulating lymphocytes also 
play a role in the inflammatory-mediated progression of NASH and in particular 
polymorphonuclear leukocytes, T-cells and natural killer (NK) cells, Figure 1.2. 
 
 
 
 
Figure 1.3: Subpopulation of cells in the liver. Liver is composed of parenchymal cells (hepatocytes) and 
nonparenchymal cells including endothelial cells, stellate cells, cholangiocytes and Kupffer cells (KC). 
Other immune cells (T-cells, NK cells, or leukocytes) can infiltrate the liver in disease conditions such as 
NASH. 
 
Sinusoidal endothelial cells are generally activated in NAFLD due to increased 
circulating levels of proinflammatory cytokines, endotoxins, ROS and VEGF 150. 
Activation of endothelial cells leads to the production of cytokines, which further can 
activate other immune cell 151. Furthermore, local release of chemotactic molecules and 
cytokines from damaged hepatocytes activate the expression of adhesion molecules 
(ICAM, CD31, and E-selectin) in endothelial cells leading to infiltration of leukocytes 
152.  
 
Kupffer cells activation is positively correlated with NASH 153, 154. Activation of KC in 
hepatic steatosis is achieved by multiple pathways. Circulating endotoxin and alarmins 
released from necrotic hepatocytes such as DNA fragments, heat shock proteins (HSPs) 
and nuclear high mobility box protein 1(HMBP1) activate toll-like receptors on KC 155, 
Figure 1.4. Other activating factors also include ROS, FFA, lipid hydroperoxides, 
hypoxia, MCP-1 and complement factors C3 and C5a 155. Most recently, prostaglandin 
E2 produced by KC has been shown to stimulate the secretion of oncostatin M from 
KC which induces SOCS3 expression in the hepatocyte and causes hepatic insulin 
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resistance and steatosis156. Upon activation, KC express adhesion molecules 
(CD11b/CD18), which attract and recruit leukocytes to the liver 75. Further, KC 
releases cytokines such as TNFα, IL-1β, nitric oxide and IL-6, which activate other 
immune cells and amplify the immune response 75. Direct activation of NADPH 
oxidase (NOX-2) in KC and leukocytes leads to the production of ROS which causes 
further damage and stimulation of proinflammatory signaling in the liver 75. It is 
noteworthy to mention that KC also a play critical role in the resolution of 
inflammation by clearing out the infiltrated leukocytes 157.   
 
Additional cross talks originate from the stellate cells.  Release of TNFα and TGFβ1 
triggers transformation of stellate cells from the vitamin A-storing phenotype to the 
myofibroblastic phenotype, resulting in production of collagen types I and III and 
development of fibrosis 105. Stellate cells can also be activated by long-chain 
polyunsaturated fatty acids and ROS, which may explain the observed low-grade 
hepatic fibrosis associated with obesity, insulin resistance and after high fat feeding 105.  
 
 
Figure 1.4: Cross talk between Kupffer cell and hepatocyte in the 
pathogenesis of NASH. Proinflammatory cytokines and molecules 
generated from stressed and damaged hepatocytes stimulate 
Kupffer cells to release further cytokines. Furthermore, these 
cytokines attract other immune cells to the liver and amplify the 
damage further. HSP: heat shock proteins. CXC: chemotactic 
substances  
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1.1.6 Role of anti-inflammatory pathways in development of NASH 
Eicosanoids (prostaglandins, prostacyclins, thromboxanes and leukotrienes) are 
signaling molecules that are synthesized from arachidonic acid, docosahexaenoic acid 
(DHA) or eicosapentaenoic acid by the action of two families of enzymes 
cyclooxygenase (COX) and lipooxygenase 158. They display anti-inflammatory actions 
and play a major role in the interaction between hepatocytes and endothelial cells with 
KC and other immune cells.  
 
The enzymatic action of COX 1-2 (targets of NSAIDs drugs) leads to the formation of 
prostaglandin H2 which is later converted into different types of prostaglandins and 
thromboxanes 158, 159. The COX-derived PGE2 from Kupffer cells was demonstrated to 
inhibit basal and TGFβ1-mediated collagen synthesis by the stellate cells 160. More 
positive effects of PGE2 are evident in the improvement of liver microcirculation and 
suppression of LPS-induced TNFα, NO, and ROS release through the stimulation of 
PGE2 receptor EP4 161-163. However, contradicting findings were obtained from a study 
in which in vivo treatment with a COX-2 inhibitor attenuated the progression to NASH 
in a steatotic mouse model 164.  In this model, COX2 inhibitor treatment caused 
decreased hepatic TAG accumulation via the upregulation of PPARα 165, 166, hence 
eliminating the first hit.  However more studies should be conducted before considering 
the therapeutic role of PGE2 in the development of NASH. Studies have shown some 
unwanted effects of PGE2 on hepatocytes. PGE2 attenuated insulin signaling in rat 
hepatocytes by an EP3-R mediated activation of ERK1/2 that causes serine 
phosphorylation of IRS 167. PGE2 also stimulates the secretion of oncostatin M from 
Kupffer cells which acts on hepatocytes and induces insulin resistance and steatosis 
through the activation of lipogenesis and inhibition of VLDL secretion 156.  
 
Lipoxins are generated from arachidonic acid via the lipoxygenase-mediated 
transcellular biosynthesis. The latter term describes the process of synthesis of a 
metabolic intermediate by a donor cell and the formation of the active metabolite by 
another cell 168, 169. In the liver, this process has been shown in the interactions between 
KCs, endothelial cells and hepatocytes. Hepatocytes express the 15-lipoxygenase 
enzyme that generates 15-hydroxyeicosatetraenoic acid (15-HETE) from arachidonic 
acid. 15-HETES is then catalyzed to lipoxin LXA4 by the Kupffer cell enzyme 5-
lipooxygenase (5-LO) 170.  In addition, in the KCs 15-HETE is also generated by the 
action of aspirin-acetylated COX-2 enzyme which later gets transformed by the KC or 
neutrophil 5-LO into the aspirin triggered 15-epi-LXA4 170. 15-epi-LXA4 and LXA4 
have been found to modulate the actions of transcription factors (e.g., PPARα) and 
regulate cytokine production and chemotactic properties of hepatic cells 171-174. 
Furthermore, lipoxins and aspirin-triggered leukotrienes inhibit proinflammatory 
actions and the recruitments of neutrophils to the liver 171. Recently, it has been shown 
that lipoxins stimulate lipid disposal by enhancing the expression of PPARα in 
hepatocytes suggesting additional NAFLD protective actions173.  	  
1.1.7 Insulin resistance in NASH progression 
The action of insulin is initiated through its binding to the extracellular α-subunit of the 
insulin receptor which activates the intracellular tyrosine kinase domain of the β-
subunit 175. Receptor autophosphorylation results in insulin receptor substrate (IRS-1 
and 2) phosphorylation and IRS-associated phosphatidylinositol 3 phosphate kinase 
(PI3K) activation. PI3K consists of a regulatory subunit, p85, and a catalytic subunit 
p110. Phosphatidylinositol (3,4,5)-trisphosphate, generated by PI3K, recruits the 
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protein kinase B (PKB or Akt) to the plasma membrane, which then gets activated 
through the phosphorylation of serine 473 by mTORC2 and threonine 308 by PDK1 
175. Akt activation mediates the downstream effects of insulin such as inhibition of 
gluconeogenesis and glycogenolysis. Insulin resistance results from defects in the 
insulin signaling cascade and is commonly observed in patients with NAFLD and 
NASH. In inflammatory conditions, serine phsophorylation of the insulin receptor or 
IRS inhibits signal transduction and activation of downstream Akt176. Figure 1.5 
summarizes some of the factors which inhibit the insulin signaling cascade including 
ceramides, DAG activated PKC isoforms and ROS 177-180.  
 
Figure 1.5: Mechanism of cellular insulin resistance. Excess lipid intermediates in the TAG biosynthetic 
pathway, such as diacylglycerol (DAG) and free fatty acid (FFA) cause insulin resistance by activating 
several serine/threonine kinases, including protein kinase C (PKC), mammalian target of rapamycin/p70 
S6 kinase (mTOR/S6K), and c-Jun N-terminal kinase (JNK), which inhibits insulin signaling either 
directly through serine phosphorylation of insulin receptor substrates (IRS)-1 and IRS-2 or indirectly 
through a series of transcriptional events mediated by nuclear factor NFkB. This, in turn, results in 
reduced insulin activation of phosphatidylinositol (PI) 3-kinase and Akt. Ceramide can also impair insulin 
action through interactions with Akt. Increased levels of monomeric p85 competitively inhibit the binding 
of the p85/p110 heterodimer (PI3K) to the phosphorylated IRS-1.   
 
 
Peripheral insulin resistance results in enhanced lipolysis and impaired lipid storage as 
a result of reduced inhibition of hormone-sensitive lipase (HSL) and reduced activity of 
transcription factors involved in lipid droplet formation, such as PPARγ 181. High 
plasma insulin, FFA and glucose all together enhance DNL in the liver and cause 
hepatic steatosis 107. Insulin resistance in obesity is also accompanied by elevated levels 
of plasma proinflammatory cytokines TNFα, IL-6 or IL-1β, which promote liver 
toxicity as described earlier 182. This data indicates that insulin resistance could be 
considered a causative factor for NAFLD. However, several mouse models have shown 
that NAFLD or NASH can occur without major deterioration in whole body insulin 
sensitivity 183. Such models include those with defective uptake of lipid in peripheral 
tissues like CD36 and skeletal muscle specific-LPL deletion. In addition, mouse models 
of reduced hepatic β-oxidation or VLDL secretion are non-obese but present with 
hepatic steatosis; these include the MCD-fed mice and mice with deletion of PPARα, 
MTTP, or ACOX 39, 183. In humans, SNPs identified in the DGAT2 and PNPLA3 
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genes, involved in TAG packaging, has been shown to be associated with fatty liver but 
not with insulin resistance 184, 185. This suggests that the pattern of lipid mobilization 
and partitioning plays a major role in the dissociation/association between insulin 
resistance and hepatic steatosis.  
 
 
1.2 ROLE OF GROWTH HORMONE IN REGULATION OF HEPATIC LIPID 
CONTENT 
Growth Hormone (GH) is the key regulator of body size in mammals and an important 
regulator of lipid and glucose metabolism. GH is secreted by the pituitary gland and 
binds the GH receptor in target cells where it activates various signaling pathways 
including JAK2, STAT5b, PI3K, MAP kinase, PKC, and phospholipase A2 186. In the 
liver, the GH signal cascade induces the transcription of specific genes, such as IGF-1, 
IGF-binding proteins (IGFBPs), the acid-labile subunit (ALS), and SOCS proteins 186. 
GH metabolic actions can be exerted directly or indirectly, by IGF-1 or adipocytokines, 
or can be part of GH antagonism of insulin signaling 186. The main actions of GH are 
anabolic in muscle resulting in increased lean body mass from the promotion of protein 
synthesis combined with a reduction of nitrogen excretion. By promoting adipose tissue 
lipolysis and hepatic lipid mobilization GH increases circulating fatty acids and 
promotes their utilization in muscle at the expense of glucose. The end result is that GH 
has hyperglycemic (diabetogenic) actions. The lipolytic actions of GH in adipose tissue 
results from enhancing hormone-sensitive lipase activity and stimulation of the β-
adrenergic receptors 187. GH does not increase the lipoprotein lipase (LPL) activity in 
the adipose tissue which suggests no direct effects of GH on triacylglyceride uptake in 
adipose tissue 188. Finally, GH also reduces circulating leptin and increases resistin 
levels, while the effect on adiponectin remains controversial 188. In liver and unlike its 
action on adipose tissue, GH induces triacylglyceride uptake by increasing LPL, 
hepatic lipase and LDL receptor expression 188. Furthermore, GH induces hepatic DNL 
through the induction of fatty acid synthase (FAS) and Stearoyl-CoA desaturase 
(SCD1) expression. These activities are counteracted by enhanced hepatic VLDL 
secretion 189, 190 in connection to GH induction of apoB48 and MTTP proteins levels189, 
190. The end result of GH actions in liver is reduction of TAG accumulation. Patients 
with NAFLD have lower plasma GH levels than controls 191. Adult GH deficiency 
(GHD) is associated with NAFLD 192, 193 and patients characteristically develop 
abdominal obesity with increased total plasma cholesterol and triacylglycerides and 
decreased high-density lipoprotein (HDL)-cholesterol levels, resembling the metabolic 
syndrome 194. In addition, 29% of children with GH deficiency developed NAFLD after 
cessation of GH therapy 194.  Reduced steatosis is observed in GH transgenic mice and 
after GH replacement therapy in adults with GH deficiency.  
 
The protective action of GH on liver steatosis has also been highlighted in genetic 
studies showing hepatic inactivation of the GH receptor (GHR) 195, 196, its associated 
kinase, JAK2 197 or its downstream signaling intermediary STAT5b 198 leads to hepatic 
steatosis. Due to the disruption of hepatic IGF-1 production, the negative feedback 
regulation on GH secretion is disrupted and these mice exhibit elevated circulating 
levels of GH. A very recent study showed that abrogation of GH rescued the 
development of fatty liver in the JAK2 knockout mice 199. In this context, increased 
steatosis was attributed to the GH-augmented adipose tissue lipolysis and subsequent 
increase in circulating FFA levels197.  The net effects of GH on hepatic lipid 
metabolism might be influenced by GH antagonism of insulin signaling 200. Compared 
  
18 
to treatment with GH alone, in vivo co-stimulation with insulin results in lower hepatic 
TAG content despite lower VLDL secretion 201. These findings suggest that the effect 
of GH on hepatic triacylglyceride secretion is dependent on the GH antagonism of 
insulin actions in the liver while hepatic TAG content may also be influenced by the 
GH antagonism of insulin anti-lipolytic actions in adipose tissue.  
 
 
1.3 METABOLIC ACTIONS OF SOCS PROTEINS 
The suppressor of cytokine signaling (SOCS) protein family comprises eight different 
intracellular proteins (SOCS 1-7 and CIS) whose functions are to regulate cellular 
sensitivity to cytokine and growth factor signals. SOCS regulate JAK kinase associated 
cytokine receptors (e.g. those for leptin, GH, interferons and erythropoetin) but also 
tyrosine kinase receptors such as those responsive to insulin, IGF-1, SCF and EGF 186, 
202. Studies using genetic inactivation of different SOCS proteins in mice have 
demonstrated that individual SOCS protein have specific physiological functions. 
   
All SOCS proteins are characterized by a centrally located SH2 domain, an amino-
terminal domain of variable length and sequence, and a carboxyl-terminal 40-amino-
acid module known as the SOCS box. The function of the SOCS box is the recruitment 
of an ubiquitin-transferase system. The SOCS box interacts with Elongins B and C, 
Cullin5, Rbx 2 and E2 ubiquitin conjugating enzymes to form an E3 ubiquitin ligase 
complex. Thus, CIS/SOCS family proteins, as well as other SOCS-box-containing 
molecules, probably function as E3 ubiquitin ligase to mediate the ubiquitination and 
possibly the proteasomal degradation of targeted proteins 203. The recognition of 
targeted proteins by SOCS is thought to be mediated by the SH2 domain binding to 
tyrosine phosphorylated targets. Additional mechanisms may also be involved SOCS 
regulation of cellular signaling. Both SOCS1 and SOCS3 exhibit homology within a 
12-residue sequence known as the kinase inhibitory region (KIR) 204. The KIR binds to 
the activated JAK and can act as a JAK pseudosubstrate preventing the access of other 
legitimate substrates to the JAK catalytic pocket, thus inhibiting its activity. .  
 
1.3.1 SOCS-1 and SOCS-3:  
In multiple cell lines, SOCS1 and SOCS3 have been shown to bind IRS-1 and IRS-2 
and promote their ubiquitination and proteosomal degradation 205. Mutations in the 
SOCS box domain of SOCS1 inhibit the ubiquitination and degradation of IRS-1 and 
IRS-2 205. Hepatic expression of SOCS1 and SOCS3 has been reported to be elevated 
in rodent treated with GH and in models of obesity and insulin resistance 206. 
Furthermore, db/db mice treated with SOCS1 and SOCS3 antisense oligonucleotides 
show improvement in insulin signaling and hepatic lipid accumulation 206. In addition, 
hepatic short-term overexpression of SOCS1 or SOCS3 attenuated STAT3 activity 
which causes induction of lipogenesis via SREBP1c activation206. In vivo over-
expression of SOCS3 in adipocytes leads to a reduction in IRS-1 protein which causes 
diminished glucose uptake and reduced lipogenesis 207, 208. In addition, these SOCS3 
transgenic-mice were resistant to the development of diet-induced obesity and its 
associated insulin resistance. On the other hand, TNF-α-induced IRS-1 and IRS-2 
degradation was suppressed in adipocytes of SOCS3 deficient mice209 
 
The previous results suggest that SOCS3 negatively regulates insulin signaling 
contributing to hepatic steatosis. However, opposite findings were observed when this 
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concept was tested in SOCS3 liver specific knockout mice.  These mice developed 
hepatic steatosis after high fat diet feeding 210. The author hypothesized that the 
differences observed are due to unknown hypothalamic effects of liver specific SOCS3 
deletion that result in increased food intake and decreased energy expenditure 210, 
which were absent in other short-term in vivo or cell culture based studies 205 206. 
 
SOCS1 exerts negative inhibition of the INFγ signaling and SOCS1-/- mice die before 
weaning from multiorgan inflammatory disease that is manifested in liver by severe 
steatohepatitis. This phenotype could be rescued by concurrent deletion of the INFγ 
gene 211. In the liver, SOCS1 also downregulates hepatic growth factor (HGF) signaling 
and displays anti-oncogenic properties in the liver 212. Inhibition of hepatic SOCS1 
expression in db/db mice enhances hepatic insulin sensitivity and reduces of hepatic 
steatosis 206 suggesting a role for SOCS1 in the pathogenesis of NASH.  
 
1.3.2 SOCS 6 and 7: 
Recent studies have shown the involvement of SOCS 6 and 7 in insulin signaling 213, 
214. SOCS6 has been shown to bind to the monomeric p85 regulatory subunit of PI3 
kinase enhancing the activity of the catalytic subunit and increasing insulin sensitivity 
213. Accordingly, over-expression of SOCS6 in mice results in improved glucose 
tolerance and insulin sensitivity 213. On the other hand SOCS6-/- mice do not display 
any abnormalities in glucose homeostasis 215 suggesting that SOCS6 activity on insulin 
signaling may be redundant. SOCS7 is a close homolog of SOCS6, sharing greater than 
50% identity in the SH2 domain, and it has also been reported to interact with PI-3 
kinase. SOCS7-/- mice display improved glucose tolerance and enhanced insulin 
sensitivity compared to the wild-type mice 214. These mice display increased islet size 
due to enhanced insulin sensitivity at the β-cells level.  
 
1.3.3 SOCS2: 
GH receptor activity is counteracted through a negative feedback loop exerted by 
SOCS2, which interacts and inhibits GH receptor signaling 216, 217. The gigantism 
observed in SOCS2–/– mice is not observed in other mouse models of SOCS 
inactivation and identifIes this proteins as the key negative regulator of GH receptor 
signaling in vivo 186. In agreement, overgrowth in SOCS2-/- mice was attenuated in the 
double SOCS2/STAT5b knockout mice or in SOCS2-/- mice made GH deficient 218. 
GWAS studies have identified SNPs in the vicinity of SOCS2 associated to increased 
postnatal growth 219. A single patient has been identified with a mutation within the 
SH2 domain of SOCS2, he presented with acromegaly with normal plasma GH levels 
and plasma IGF1 in the upper limit of normal 220. In a Japanese cohort, several SNPs in 
the SOCS2 gene promoter region were found to be associated with increased risk of 
type 2 diabetes 221. Further studies are needed to elucidate the exact mechanism 
whereby SOCS2 acts on insulin signaling. 
 
Despite the increased GH activity in SOCS2-deficient mice (SOCS2-/-), these mice 
show normal glucose tolerance and insulin sensitivity, which may be attributed to the 
increased lean body mass and reduced levels of GH observed in these mice 222. Under 
normal dietary conditions, SOCS2-/- mice exhibit reduced TAG accumulation in the 
liver. SOCS2 has been shown to have other functions related to neuronal development, 
bone growth, estrogen and glucocorticoid signaling and inflammation 223. The later 
SOCS2 function is relevant in our discussion of the role of inflammation in the 
progression of NAFLD. SOCS2 has shown anti-inflammatory properties and its mRNA 
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and protein levels were induced by anti-inflammatory mediators such as lipoxin 
(LXA4) 223. In addition, aspirin’s anti-inflammatory actions and inhibition of NF-κB 
signaling is found to be SOCS2 dependent in mice 223.  Furthermore, SOCS2-/- mice 
have abnormal leukocyte infiltration, an uncontrolled production of proinflammatory 
cytokines leading to higher mortality observed after infection 223. Recently, SOCS2 was 
implicated in the acceleration of dendritic cell (DC) maturation, an antigen-presenting 
cell of the innate immune system 224. Furthermore, SOCS2 deletion in DC enhanced 
TLR signaling and increased the STAT3 mediated expression and secretion of IL-1β 
and IL-10 225 224. Overall, the anti-inflammatory role of SOCS2 might suggest a 
protective role in the development of NASH.  
 
1.3.4 Cullin-RING-Ligase system 
SOCS are thought to target cellular signaling intermediates for degradation via the 
ubiquitin-proteasome system. Ubiquitin, a small conserved protein of 76 amino acids, 
is first conjugated to the E1-ubiquitin activating enzyme. This is an ATP-requiring 
thioesterification reaction between the C-terminal glycine residue of ubiquitin and the 
sulfahydryl group of cysteine residue in the E1. Ubiquitin is then transferred from the 
E1 to a cysteine residue of the E2 (ubiquitin conjugating enzyme, UBC) enzyme. 
Almost 30-40 UBCs exist in the human genome. Finally, through the action of a 
ubiquitin ligase (E3), ubiquitin is transferred to a lysine residue in the target protein, 
Figure 1.6. The Lys48-linked polyubiquitination chain on target proteins makes them a 
substrate for the 26S proteasome 226.   
 
 
Figure 1.6: Protein ubiquitination system. Ubiquitin (UB) molecule is activated by 
the ubiquitin activating enzyme (E1) and then conjugated to the ubiquitin 
conjugating enzyme (E2). The ubiquitin ligase (E3) recognizes the target substrate 
and catalyzes the transfer of UB molecule.  
 
Two main classes of E3 are evident at the primary sequence level: those bearing a 
HECT (Homologous to E6-AP C-Terminus)-type catalytic domain and a prominent 
class containing a RING (Really Interesting New Gene) domain. In contrast to HECT-
type E3 enzymes, which contain an active cysteine residue and form an obligate 
thioester bond with ubiquitin prior to transfer to the substrate. RING-type E3s serve as 
a docking site for the ubiquitin-activated E2, which provides the catalytic activity 226.  
 
The largest E3 superfamily consists of the multisubunit Cullin-RING ligases (CRLs). 
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CRLs consist of an extended cullin scaffold interacting with a catalytic RING-
containing protein, either Rbx1 or Rbx2 226. The human genome encodes at least seven 
cullins including CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5 and CUL7.  They 
form around 300 distinct CRL complexes in different subfamilies (CRL1 containing 
CUL1, CRL2 containing CUL2, etc.). SOCS2-7 and CIS interact with the 
Cullin5/Rbx2 complex while SOCS1 interacts with Cullin2/Rbx1.  
 
1.3.4.1 Substrate recognition by CRL 
 
Even though CRL subclasses contain the same catalytic core, they use different 
substrate-recognition modules. In most cases these modules use a BTB (Bric-a-Brac, 
Tramtrack and Broad complex)-fold adaptor to interact with the amino-terminal 
domains of cullins, and thus provides specificity for the interaction with the various 
substrate-recognition modules 227. In the classical SCF (Skp1-Cullin-F-box), the BTB-
fold adaptor SKP1 connects	   the CUL1 to F-box proteins, which recognize their 
substrates through various substrate interaction motifs, such as WD40 motifs or 
Leucine Rich Repeats (LRR). In CRL2 and CRL5 complexes, the BTB-fold adaptor 
Elongin C connects CUL2 and CUL5 to BC-box proteins (e.g. SOCS box), which in 
turn binds their substrates primarily through LRR, ankyrin repeats or SH2 domains228. 
Despite the fact that both CUL2 and CUL5 use the same adaptor, they engage different 
classes of substrate-recognition subunits, termed VHL-box and SOCS box proteins 
respectively 228.  The ubiquitin-like protein Elongin B is also part of CRL2 and CRL5. 
In CRL3 complexes, a single polypeptide fulfils the function of SKP1/ElonginC and F-
box/BC-box dimers and bridges CUL3 to substrates 227. Illustrations of these examples 
are displayed in Figure 1.7. 	  
1.3.4.2 Catalytic domain of CRL 
 
The C terminal of CRL consists of the same catalytic core composed of a cullin-RBX1 
heterodimer bound to the E2-ubiquitin, except for CUL5, which also binds RBX2. In 
the CRL complex, the ubiquitin molecule on the E2 is spatially distant from the 
substrate and hence to activate the ubiquitin transfer the cullin protein gets covalently 
neddylated at a conserved lysine residue present in all cullin family members, Figure 
1.8. Neddylation requires the ubiquitin-like protein NEDD8 (Neural precursor cell 
Expressed Developmentally Down-regulated protein 8) 229. NEDD8 attachment 
stimulates multiple CRL ubiquitin E3 activities by promoting the binding to E2-
ubiquitin, enhancing ubiquitin transfer from the E2 active site, and by positioning the 
E2 active site adjacent to the substrate. The NEDD8 conjugation is catalyzed by two 
NEDD8-specific E2s, Ubc12 and UBE2F, that interact with the two different RBX 
proteins to modify specific cullins 230. For example, UBE2F and Rbx2 neddylate 
CUL5. Cullins get deneddylated by a multisubunit enzyme named the COP9 
Signalosome (CSN) 229. The catalytic component, CSN5, is a member of the zinc 
metalloproteinase family. Another mechanism of CRL activation might include 
dimerization through the substrate recognition motif or the NEDD8-cullin; although 
CUL2 and CUL5 CRL complex has only been observed as monomers 231, 232. It is 
worth mentioning that CRL can be inhibited via CAND1 (Cullin-Associated and 
Neddylation- Dissociated 1). CAND1 binds specifically to free cullin-Rbx complexes 
lacking NEDD8 and inhibits CRL assembly and NEDD8 activation 233. 
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Figure 1.7: Composition of cullin-RING E3-ligases (CRLs). CRLs are formed around a cullin scaffold 
protein, which recruits the substrate-recognition module (SRM) through its N-termini and the catalytic 
site through its C-terminal part. The basic composition of a CRL with CUL1, CUL2, CUL3 and CUL5 
are illustrated and described in the text.  The catalytic module contains the RING domain (Rbx1 or 
Rbx2) and hosts the E2 enzyme which catalyzes the transfer of ubiquitin to the substrate. The N-terminal 
of cullin contains a docking site for a BTB domain present in the adaptor molecules. In CRL2 and 5, the 
substrate interaction motif (SIM) represents the SH2 domain in SOCS protein which specifically bind to 
phosphorylated substrates 
 
 
 
 
Figure 1.8: Regulation of the CRL system. Neddylation of CRL is catalyzed by conjugation of NEDD8 
via E2 enzymes Ubc12 and UBE2F. CSN and CAND1 are involved in the deactivation of the CRL 
complex.  
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2 AIM OF THE STUDY 
The main goal of this thesis is to evaluate the mechanism of actions and physiological 
significance of SOCS2 and SOCS6 proteins. We hypothesised that SOCS2 and SOCS6 
play important roles in the regulation of hepatic insulin and GH signalling and also 
hepatic lipid content. We therefore aimed to: 
 
 
• To explore the E3-ligase activity of SOCS proteins toward cytokine and growth 
factor receptors. Paper 1 and 4. 
• To investigate the physiological of role of SOCS2 in the control of hepatic 
metabolism in conditions of dietary stress. Paper 2 
• To investigate the role of growth hormone-SOCS2 axis in understanding the 
pharmacological actions of the LXR ligands on hepatic lipid metabolism. 
Paper 3 
• To characterize the structural binding of SOCS6 to target proteins. Paper 4 
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3 MATERIALS AND METHODS 
3.1 ANIMAL AND CELL MODELS 
In the studies presented in this thesis we have used the SOCS2-/- mice (C57BL/6J) 
previously described 234. Animal experiments were held in the animal facilities at the 
university Las Palmas of Gran Canaria, Canary Islands, Spain and Karolinska Institutet, 
Sweden. To induce diet-induced insulin resistance and obesity, mice fed a regular chow 
diet (CD) (SAFE-diet A04, Panlab SLU, Barcelona, Spain) or high fat diet (HFD, 
OpenSource DIETS, D12492) ad libitum for 2 and 4 months. The high-fat diet 
contained 34.9% fat, 26.3 % carbohydrate, and 26.2 % protein per unit weight. Bone 
marrow derived macrophages were isolated from SOCS2-/- mice, cultured and used to 
study TLR4 receptor signalling. Primary human hepatocytes were isolated from healthy 
human liver tissue from donors in hepatic transplants. All human and animal 
experimental protocols were according to the Karolinska Institutet and University of 
Las Palmas Gran Canaria ethical guidelines (ethical permits No. 2010/678-31/3, 
N415/08, N46/11 and N363/08). Isolated hepatocytes were obtained from the liver cell 
laboratory, KI-CLINTEC, Huddinge University Hospital. Cells were maintained in 
Williams E medium as described previously 235. GH signaling was studied in BRL4 
cells, which are stably transfected with the rat GHR gene and express endogenous 
JAK2 and STAT5b 236 (paper III). To study the ubiquitin ligase activity of SOCS2 and 
SOCS6, transient transfection of GHR and c-KIT were performed in HEK293T cells 
(paper I and IV). 
 
Table 3: Calorie contents of diets used in the study (% of total calories) 
 Control diet (CD) High fat diet (HFD) 
Fat 3 % 60% 
Carbohydrates 60% 20 % 
Proteins 16% 20% 
 
3.2 MEASUREMENT OF WHOLE BODY INSULIN SENSITIVITY 
Insulin sensitivity was assessed in vivo by measurement of fasting blood glucose, 
fasting plasma insulin, intraperitoneal glucose tolerance test (ipGTT), intraperitoneal 
insulin tolerance test (ipITT), and homeostatic model assessment of insulin resistance  
(HOMA-IR). Plasma insulin levels were measured using commercial ELISA kits.  For 
ipGTT, mice were fasted 16 h overnight followed by an i.p. injection of D (+)-glucose 
(20% in 0.9% NaCl) at a dose of 2g/kg body weight. Blood glucose levels were 
measured using a glucometer (Roche Diagnostics, Basel, Switzerland). For ipITT, 
human insulin was intraperitoneally injected into 4-h fasted mice at a dose of 0.75 U/kg 
body weight and glucose levels were determined as explained above. HOMA-IR was 
calculated as follows: fasting insulin (ng/mL) × fasting glucose (mM).  
 
3.3 ASSESSMENT OF PANCREATIC FUNCTION 
We characterized the SOCS2-/- pancreatic phenotype by measuring plasma insulin at 
fasting and 10 minutes after ipGTT (index of insulin secretion). We also analyzed 
pancreatic insulin content and insulin/glucagon ratio by immunohistochemistry (IHC). 
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Insulin extractions were carried out overnight on pre-weighed homogenized pancreas at 
4°C under constant shaking followed by centrifugation. Supernatants were diluted 1000 
fold and insulin concentrations were determined using an ELISA kit (Ultra. Sensitive 
Rat Insulin ELISA; Crystal Chem, Downers. Grove, IL, USA). Paraffin embedded 
tissue was sectioned for insulin and glucagon immunostaining. Primary antibodies were 
detected with an appropriate biotinylated secondary antibody in conjunction with 
Vectastatin ABC peroxidase kit (Vector Laboratories, Carpenteria, CA) and chromogen 
diaminobenzidine (Sigma, St. Louis, MO). Slides were counterstained in hematoxylin 
and eosin. We further calculated HOMA-β cell function as follows: 20 × fasting insulin 
(µU/mL)/fasting glucose (mmol/L) − 3.5.  
 
3.4 IN VIVO HEPATIC TRIACYLGLYCERIDE SECRETION ASSAY 
Triacylglyceride secretion rate in vivo was measured by intravenous administration of 
Triton WR-1339 (Sigma, St. Louis, MO, USA) which blocks the peripheral hydrolysis 
of triacylglycerides. The animals were fasted for 6 h to avoid the influence of 
chylomicrons from the intestine. Thereafter, they were injected intravenously with 
Triton WR-1339 diluted in saline (200 mg/ml) via the tail vein (500 mg/kg body 
weight). Blood samples were taken before the injection (baseline fasting 
triacylglyceride concentration) and 30, 60 and 90 min after Triton WR-1339 
administration. The triacylglyceride accumulation was linear during this time period. 
Total plasma content of triacylglycerides was calculated using the published plasma 
volume in male mice (0.071 ml/g). Hepatic triacylglyceride secretion rate, expressed as 
total µmol TAG/min was calculated from the slope of the curve. 
 
3.5 MULTIPLEX IMMUNOASSAY 
Multiplex technology allows the simultaneous qualitative or quantitative analysis of 
analytes using color-coded microspheres in a single tube or well. We utilized flow 
cytometric multiplex arrays, also known as bead-based multiplex assays. Different bead 
sets employ properties (e.g. size or fluorescence), which are distinguishable under flow 
cytometry. Each bead set is coated with a specific capture antibody, and fluorescence or 
streptavidin-labelled detection antibodies bind to the specific cytokine-capture antibody 
complex on the bead set. This allows the identification and quantification of various 
analytes using one sample volume. 
 
In our study we employed multiplex technology to quantify cytokine levels IL1β, IL-6, 
interferon (IFN) γ, TNFα, and RANTES. Cytokine levels were measured both in 
plasma and media collected from cell cultures. The multiplex assay was also used to 
quantify AKT, JNK , and  IRS1 phosphorylation in tissue homogenates. Traditional 
single analyte ELISA kit were used to measure plasma GH, IGF1, leptin and insulin 
levels.  
 
3.6 PLASMID CONSTRUCTION AND IN VITRO MUTAGENESIS 
In paper IV, we constructed the pFlag-SOCS6 expression plasmid using PCR-based 
technology and ligation, Figure 3.1. The human SOCS6 open reading frame was 
obtained from a commercial source (Invitrogen, Carlsbad, CA). A DNA fragment 
containing the full length human SOCS6 was amplified by PCR using a high fidelity 
Pfu DNA polymerase and cloned into the pFlag-CMV2 vector (Sigma-Aldrich) to 
express a N-terminally Flag-tagged version of hSOCS6 in mammalian cells. To insert a 
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mutation in the cloned gene, we applied site-directed mutagenesis. Two complementary 
primers are designed to carry the mutation of interest. Thereafter, these primers anneal 
with the wild type methylated plasmid and create a mismatch at the mutation site. Then 
PCR reaction is carried out using a high fidelity DNA polymerase to synthesize a new 
non-methylated plasmid from the two primers carrying the mutation. Before cellular 
transformation, the wild type plasmid is removed by the action of the Dpn1 enzyme, 
which digests the methylated DNA only, Figure 3.1. Insert and mutant sequences were 
then confirmed by DNA sequencing. 
 
Figure 3.1: In vitro site directed mutagenesis. The wild type plasmid 
contains the SOCS gene of interest tagged with a Flag peptide sequence 
at the N terminal. The expression of the Flag-SOCS gene is driven by a 
strong cytomegalovirus promoter (CMV). Mutant plasmid can be 
generated by PCR reaction using set of complementary primers (red). 
Newly in vitro synthesized plasmid (red) will be non-methylated while 
the methylated-wild type plasmid (blue) will be digested by the enzyme 
Dpn1. 
 
 	  
3.7 IN VITRO E3-LIGASE ASSAY  
To determine the E3 ligase activity of SOCS2 and SOCS6, cells were transiently 
transfected with Flag-tagged SOCS2 or SOCS6.  Elongin B and C were co-transfected 
to increase the stability of the SOCS proteins. Complexes of SOCS proteins and their 
associated proteins were immunoprecipitated by anti-Flag-agarose beads (Sigma-
Aldrich). The E3 ligase assay was carried out on the precipitated SOCS protein 
complexes by adding the other components of ubiquitination reaction in an appropriate 
buffer: E1 enzyme (human recombinant, Enzo Life Sciences, Inc.), E2 (UbcH5b), 
ubiquitin, HA-tagged ubiquitin, ATP, MgCl2, creatine phosphate, rabbit skeletal muscle 
creatine kinase (Calbiochem, La Jolla, CA).  Reactions were carried at 37 oC for 30 min 
  
27 
and stopped by the addition of protein electrophoresis sample buffer, followed by SDS-
PAGE. An anti-HA antibody was used to detect incorporation of ubiquitin into high 
molecular weight protein conjugates. The intensity of this signal was used to evaluate 
ubiquitin ligase activity. To detect polyubiquitination of specific target proteins, a 
parallel set of experiments was carried and reactions were stopped by addition of 
EDTA (to chelate Mg+2 ions), followed by elution with Flag peptide (Sigma-Aldrich). 
This is to recover the SOCS6-containing complexes from the anti-flag agarose beads. 
Then target proteins were immunoprecipitated from the elution samples using specific 
antibodies followed by immunoblotting with anti-HA to detect ubiquitin or a specific 
antibody to detect the shift in molecular weight of the target protein. Figure 3.2 
illustrates the steps of the E3 ligase assay.  
 
 
Figure 3.2: In vitro E3-Ligase activity. Western blot against anti-HA is used to detect HA-tagged 
ubiquitin (HA-Ub) in the ubiquitinated target proteins. E3 ligase activity can be stopped by EDTA and 
flag-beads are eluted by flag peptide. Ubiquitination of a specific target protein can be detected after 
immunoprecipitation and immunoblotting against the target protein or against HA-ubiquitin  
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3.8 LUCIFERASE ACTIVITY ASSAY 
The luciferase reporter assay has been widely used to study gene promoter activity. 
The pGL2 luciferase reporter vectors are designed for quantitative analysis of factors 
that potentially regulate mammalian gene expression. These vectors carry the coding 
region of wild-type firefly (Photinus pyralis) luciferase. In our study, the luciferase 
activity of pGL2 vectors was driven by the GH response element of the human 
SOCS2 gene promoter region, containing a SREBP1 binding site (E-box) and two 
STAT5b binding sites in close proximity 237. After the vector was transfected into 
cultured cells, the luciferase activity was measured using a luminometer. The light 
intensity reflects the amount of luciferase, which reflects the transcriptional activity 
of the inserted SOCS2 promoter region in relation to specific experimental condition. 
The luciferase activity was normalized to the protein content or to the β-galactosidase 
from a cotransfected vector expressing the β-galactosidase gene. 
 
3.9 CYCLOHEXIMIDE CHASE EXPERIMENTS 
Cycloheximide chase is an experimental tool used to determine the half-life of a 
specific protein. In cells, proteins are constantly being synthesized and degraded. 
Cycloheximide inhibits protein synthesis by interfering with the translation-elongation 
step. Cells are homogenized after treatment with cycloheximide at indicative time 
points. Protein cellular levels drops after cycloheximide treatment and are detected by 
western blot using specific antibodies. In this thesis cycloheximide chase experiments 
were used to examine the regulation of SOCS protein stability by Elongin C and B. In 
addition, stability of SOCS target proteins, GH receptor and c-KIT was studied after 
overexpression of SOCS2 or SOCS6 respectively.  
 
3.10 TRANSCRIPTION FACTOR BINDING ABCD ASSAY  
The ABCD assay (avidin, biotin, complex, DNA) is an experimental tool to study the 
binding of proteins such as transcriptional factors to a DNA molecule. It is an 
alternative to chromatin immunoprecipitation, in which protein-DNA complexes are 
immunoprecipitated using a specific antibody and then followed by the detection of 
target DNA elements by polymerase chain reaction. In the ABCD assay, protein-DNA 
complexes are immobilized by biotinylated oligonucleotides to a streptavidin bead 
matrix followed by detection of the bound transcription factors using a specific 
antibody by western blotting. Biotinylated oligonucleotide containing the binding site 
for a transcription factor is mixed with lysates from cells treated under different 
conditions. The mixtures were incubated overnight to allow the binding of transcription 
factors to the DNA element. This was then followed by the addition of streptavidin 
agarose beads to pull down the biotinylated oligonucleotide-protein complexes 
followed by detection of bound proteins by western blotting. In this thesis, we used the 
ABCD assay to study the binding and competition of SREBP1 and STAT5b to their 
response elements in the SOCS2 promoter.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
The SOCS2 Ubiquitin Ligase Complex Regulates Growth Hormone Receptor 
Levels 
 
Some of SOCS2 physiological functions are exerted through feedback inhibition of 
GHR signaling. GH activated STAT5b binds the promoter of SOCS2 to induce its 
expression, in turn SOCS2 binds at least two phosphorylated tyrosines on the GHR to 
negatively regulate JAK2 and STAT5b activation 218, 237. The molecular basis for these 
actions of SOCS2 is not entirely clear. In this study we tested whether SOCS2 can 
assemble an E3 ubiquitin ligase complex that targets the GHR and can modulate its 
turnover.  
 
We have demonstrated that SOCS2 interacts with elongin B and C, cullin5 and Rbx2 to 
form a canonical ECS (elongin/Cullin/SOCS) complex. (Figure 4.1A). In vitro assays 
demonstrate that this complex has intrinsic ubiquitin ligase activity and can ubiquitinate 
the GHR. This strongly suggests that this is the mechanism whereby SOCS2 controls 
GH sensitivity (Figure 4.1B). In support of this conclusion, we show that GHR levels 
decreased in cells overexpressing SOCS2 as a result of accelerated GHR degradation. 
Accordingly, elevated GHR levels were observed following SOCS2 reduction in cells 
or in livers from SOCS2-/- mice.  Our data provide a mechanistic explanation for the 
negative actions of SOCS2 on the GH activated signaling pathways.  
 
 
Figure 4.1: SOCS2 forms a stable complex with CRL5 and mediate ubiquitination 
of GHR. A, HEK293T cells were transfected with Elongin B, Elongin C and 
Myc-Cullin5 and either an empty vector (lane 1), wild type (lane 2 and 8) or a 
mutant form of FLAG-SOCS2 (lanes 3-7) as denoted in the picture. B, In vitro 
E3 ligase assays shows enhanced protein ubiquitination of target proteins in 
samples overexpressing SOCS2. Upper panel demonstrate the ubiquitination of 
GHR after E3 ligase reaction 
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Unliganded GHRs undergo constant endocytosis via clathrin-coated vesicles and are 
subsequently transported to lysosomes for degradation238. Endocytosis of the GHR is 
dependent on ubiquitination. A motif has been identified in the cytosolic portion of the 
receptor (UbE motif) that controls the GHR ubiquitination level. Mutations in this 
region hinder GHR endocytosis and degradation causing enhanced cellular sensitivity 
to GH 239. Interestingly basal GHR endocytosis can proceed even when all Lysine 
residues in the intracellular domain are mutated to Arginine 240, indicating that 
ubiquitination of associated proteins but not the GHR itself may drive this process. The 
F-box protein β-transducin repeat-containing protein (βTrCP) serves as the substrate 
recognition subunit in the SCF (βTrCP) ligase (Skp1, Cul1 and Rbx1) and has been 
shown to mediate GHR recognition through the UbE motif and promote its 
ubiquitination 241. βTrCP seems to be involved in the continuous and constitutive 
ubiquitin-dependent endocytosis of GHR 242 . In fact, the close proximity of the JAK2 
(box-1) and βTrCP (UbE) binding sites on GHR seems to preclude the regulation of 
activated GHr by this ligase. Indeed, upon GH stimulation, the phosphorylation and 
binding of JAK2 inhibits the βTrCP mediated-GHR ubiquitination and endocytosis 242. 
Mice where βTrCP gene has been inactivated do not show obvious disruption in growth 
rate implicating that either basal turnover of GHR contribute little to GH sensitivity or 
that additional E3 ligases can target the GH receptor complex in the absence of βTrCP. 
 
Endocytosis of the GHR is accelerated by ligand binding indicating the existence of a 
second E3 ligase preferentially targeting active GH receptors. Our finding that SOCS2 
mediated GHR degradation depends on the phosphorylation of Tyr487 suggest its 
involvement in the GHR downregulation after GH stimulation. This is in agreement 
with a study showing that phosphorylation of cytosolic tyrosine residues is important 
for the GH-induced GHR endocytosis 243.  The importance of SOCS2 in the control of 
GH sensitivity is validated by the gigantism observed in SOCS2-/- mice. The ability of 
SOCS2 to regulate the levels of the active mature GHR suggests that it has a pivotal 
role in conditions of altered GH sensitivity such as chronic wasting, infection and 
hyperinsulinemia 244.   
 
4.2 PAPER II 
SOCS2 inactivation protects against hepatic steatosis but worsens insulin 
resistance in high fat diet fed mice 
 
Non-alcoholic fatty liver disease (NAFLD) is associated with a wide spectrum of 
clinical and pathological manifestations. Accumulation of fat in the liver is strongly 
related to insulin resistance and associated metabolic alterations e.g. abnormal glucose 
tolerance and alterations of serum lipids. The underlying mechanisms for the 
association between insulin resistance, obesity and hepatic steatosis are not fully 
understood but recent studies show that a reduction of hepatic steatosis in obese mice is 
sufficient to restore insulin sensitivity 53. 
 
Growth hormone (GH) is a key metabolic regulator of liver triacylglyceride (TAG) 
content. Hepatic steatosis is a prominent feature in GH-deficient patients and can be 
corrected by GH replacement therapy 192. These effects are due to direct effects of GH 
on the liver as recently demonstrated by liver specific inactivation of the GH receptor 
and its downstream signaling intermediaries, JAK2 and STAT5, which in all cases lead 
to severe steatosis 245. The Suppressor of Cytokine Signalling 2 (SOCS2) is a subunit of 
an E3 ubiquitin ligase responsible for the downregulation of GH receptor signalling in 
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vivo 218. Deficiency of SOCS2 leads to an increased GH sensitivity and therefore 
SOCS2-deficient (SOCS2−/−) mice grow larger without elevation of GH circulating 
levels. In contrast to GH transgenic mice or GH-treated patients, SOCS2−/− animals do 
not exhibit deterioration of insulin sensitivity.  Sensitization to GH through SOCS2 
inhibition may provide a novel approach to regulate hepatic lipid load avoiding some of 
the limitations associated with direct GH treatment. Here we tested this concept by 
analyzing the metabolic response of SOCS2−/− mice to high-fat feeding.  
 
We found that SOCS2−/− mice are protected from high-fat diet (HFD)-induced hepatic 
steatosis through mechanisms that involve enhanced expression of genes involved in 
TAG synthesis coupled to increased hepatic TAG secretion. Paradoxically, we found 
that the effect of HFD on reducing systemic and hepatic insulin sensitivity was 
substantially more notable in SOCS2−/− mice. When investigating possible reasons why 
SOCS2−/− animals have an increased sensitivity to dietary stress, we observed enhanced 
expression of genes encoding inflammatory cytokines (IL-6, INFγ, and RANTES) in 
the liver and adipose tissue and elevated levels of these cytokines where also detected 
in blood from HFD fed SOCS2-/- mice. Measurements of macrophage cell markers and 
histological examination of SOCS2-/- mice livers did not detect any overt inflammatory 
cell infiltration, suggesting that enhanced cytokine production is due to over activity of 
the liver resident macrophages. This notion is further supported by findings that NFκB 
activity is enhanced in liver tissue of SOCS2-/- fed a HFD. By using bone marrow 
derived macrophages we could show that SOCS2 inactivation enhanced phagocytic 
activity, augmented NF-κB activation and increased production of inflammatory 
cytokines upon lipopolysaccaride (LPS) stimulation. Therefore, our findings indicate 
that SOCS2 has an important role in the regulation of hepatic homeostasis under 
conditions of dietary stress through actions on hepatic TAG secretion and in the control 
of toll-like receptor 4 signalling. These findings may be of relevance for the 
pathogenesis of NAFLD given that SOCS2 gene expression is reduced in liver from 
obese individuals 246. The reduced levels of liver SOCS2 mRNA, may be a 
consequence of reduced GH secretion that is commonly associated with obesity. 
Likewise, stimulation of SOCS2 expression by GH may be a contributing factor to the 
reversal of hepatic inflammation during replacement treatment in GH deficiency 192.   
 
The recognition that SOCS2 acts on macrophages to limit cytokine production in 
response to LPS suggest that SOCS2 could be a link for cross talk between GH 
receptors and Toll-like 4 receptors and this provides a novel mechanism for GH to 
modulate the inflammatory activity of macrophages 218, 222. Possibly, it may also help to 
explain why GH treatment exacerbates inflammation in LPS-treated rodents and can be 
life threatening when given to critically ill patients 247. 
 
In conclusion, we identified SOCS2 as a novel regulator of hepatic homeostasis in 
conditions of dietary stress. The HFD-fed SOCS2−/− mice provide a novel model to 
understand the complex relationship between inflammation and steatosis in the control 
of hepatic glucose homeostasis. Future use of this model may help to outline the 
contribution of different mechanisms related to lipid overload or inflammatory stress in 
the development of fat-induced hepatic insulin resistance.  
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Figure 4.2: Effect of SOCS2 deletion on hepatic lipid content and development of insulin resistance. 
Enhanced growth hormone sensitivity results in enhanced hepatic de novo lipogenesis coupled with 
enhanced VLDL secretion resulting in less hepatic lipid accumulation. Enhanced TLR-4 signaling in 
Kupffer cells or hepatocyte enhances the expression of inflammatory cytokines predisposing to insulin 
resistance.  
 
 
4.3 PAPER III 
A Liver X Receptor agonist Downregulates Hepatic Growth Hormone Signaling 
 
The nuclear receptor Liver X receptor-α (LXRα) controls a complex transcriptional 
network involved in the control of hepatic intracellular non-esterified cholesterol levels. 
Known LXR target genes include membrane transporters promoting cholesterol efflux, 
enzymes involved in cholesterol catabolism and genes involved in de novo 
lipogenesis248. Treatment of animals with the LXR agonist T0901317 reduces 
circulating cholesterol levels, improves insulin sensitivity but also causes severe hepatic 
steatosis and hypertriglyceridemia 249. On the other hand LXRα/β knockout mice 
(LXR-/-) are resistant to hepatic steatosis induced by high fat diet feeding 250, 251. In 
contrast GH actions promote lipid mobilization from the liver, fatty acid oxidation in 
muscle and can lead to insulin resistance.  Because of the apparent antagonistic actions 
of LXR agonist and GH, in this study we analyzed how hepatic GH signaling is 
affected by LXR activation. 
 
We showed that LXR activation impairs GH signaling in hepatocytes. LXR agonist 
treatment attenuated GH transcriptional activity in BRL-4 cells while inducing the 
expression of SREBP1c, SREBP1a and SREBP2. The inhibitory effect of the LXR 
agonist can be recapitulated by overexpression of the LXR downstream-regulated 
factors SREBP1a and SREBP2 in hepatic cells. Likewise, the activity of a reporter 
vector, driven by the STAT5b response element of the SOCS2 gene, was inhibited by a 
simultaneous treatment with LXR agonist or by overexpression of SREBP1a or 
SREBP2. Additional experiments show that SREBPs induce the degradation of 
STAT5b. Furthermore, LXR activation of primary hepatocytes results in reduced levels 
of GH receptor parallel to the down regulation of STAT5b.  Collectively, these findings 
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suggest that the mechanisms of LXR mediated inhibition of GH signaling involve the 
downregulation of the transcriptional factor STAT5b and the GH receptor.  
 
The empirical findings of LXR interference with hepatic GH signaling assist in our 
understanding of the mechanisms of GH insensitivity observed after feeding or during 
conditions such as in hyperinsulinemia. Previous studies have shown that insulin 
inhibits growth hormone activation of JAK2 and STAT5b in hepatoma cell lines 252, 253. 
Insulin is a known inducer of LXR-dependent SREBP1 expression and this may 
contribute to antagonize the diabetogenic actions GH in fed-states 252, 254. Overall, these 
findings have important implications for designing a new LXR agonist treatment 
protocols for the management of hypercholesterolemia and insulin resistance since GH 
antagonism may have wide physiological implications in multiple tissues.  More 
broadly, additional research is needed to determine the in vivo pharmacological effect 
of LXR activation on hepatic growth hormone signaling.  
 
4.4 PAPER IV 
Structural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 
(SOCS6) Ubiquitin Ligase 
 
SOCS6 was first described to associate to the IRS-4/PI3 kinase complex 213. Later 
studies have shown that SOCS6 positively regulates insulin signaling in vivo and in 
vitro. In addition, SOCS6 255, as well as SOCS1 256, 257, SOCS2, SOCS3258 can inhibit 
SCF induced cKIT-mediated cell proliferation. Furthermore, SOCS6 expression is 
downregulated in various human cancers 259 and tumour cell lines, suggesting that 
SOCS6 may also act as a possible tumour suppressor. 
 
Tyrosine kinase signaling from the SCF receptor, c-KIT is essential for the proliferation 
of mast cells, but must be tightly regulated to avert the onset of multiple human 
tumours 260, 261. We have demonstrated that SOCS6, via its SH2 domain, interacts with 
c-KIT to promote its ubiquitination and regulates c-KIT receptor turnover. The 
interaction site in the juxtamembranous region, c-KIT pY568, binds to the SOCS6 SH2 
domain with high affinity and conforms to the preferred recognition sequence 
determined for SOCS6 (pYVYI) 215. The SH2 loop arrangement is similar to SHP2, 
which also binds c-KIT pY568, but displays striking differences to other SOCS family 
members, including SOCS3, which target other cytokine receptors.  
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Figure 4.3 Binding of cKIT to SOCS6 and its ubiquitination. A, Ribbon structural demonstration of cKIT 
peptide binding to the SH2 domain pocket in SOCS6. cKIT pY568 residue is projected into a positive 
pocket between the βD and βC loops. B, In vitro  E3 ligase activity of SOCS6 and subsequent 
ubiquitination of cKIT after the ubiquitination reaction. 
 
	  
All SOCS family members are thought to be part of Cullin/Ring ubiquitin ligase 
complexes, were they act as the substrate recognition subunits (see Fig 1.7). Within the 
SOCS proteins, the SH2 domain is thought to recognize tyrosine phosphorylated 
substrates allowing the preferential targeting of signaling active proteins. The 
distinction of active and inactive targets (tyrosine phosphorylated or not) by SOCS is 
essential if they are to act as negative feedback regulators as is widely believed. E3 
ligase recognition of posttranslationally-modified substrates provides temporal and 
spatial specificity to their actions that may have important implications for their 
biological function. This is well exemplified by the differences between βTRCP and 
SOCS2 in the control of GH sensitivity but less understood for other SOCS family 
members 262.  
 
A key issue to understand the SOCS system is how substrates are recognized.  In this 
study, we show that the SH2 domain of SOCS6 binds the cKIT pY568 peptide with a 
strong affinity (Kd = 0.3 µM) comparable to the binding of SOCS4 to the pY1092 in 
the EGFR (Kd = 0.5 µM ) 263 or of SOCS3 to the pY595 of the gp130 cytokine receptor 
subunit (Kd=0.152 µM) 264. Accordingly, SOCS6 ubiquitinates c-KIT in an SH2 
dependent manner. On the other hand, several other substrates have been proposed for 
SOCS6 actions, including the phosphatidylinositol 3-kinase regulatory subunit (PIK3R) 
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1 and 2, p56LCK and STAT3 265, 266; all proteins with regulatory role in metabolism 
and inflammation. A close inspection of the known tyrosine phosphorylated residues in 
the PIK3R1 and PIK3R2 fails to recognize sites that conform to the preferred 
recognition sequence for the SOCS6-SH2 domain (pYVYI). This suggests that either 
SOCS6 can recognize substrates through lower affinity interactions, as it is the case for 
SOCS2 (Kd=1.6 µM for GHR Tyr 595) 262 or additional domains may contribute to 
substrate recognition. Indeed, the N-terminal domain of SOCS6 has been implicated to 
bind to p56LCK and STAT3265, 266 while similar domain in SOCS4 participate in the 
binding to the EGFR 263. The N-terminal domain of SOCS2 is also necessary for full 
activity towards the GH receptor 267. Additional studies are needed in order to define 
the structure of full-length SOCS proteins bound to substrates are needed, as this 
information will lead to a better understanding of the distinct physiological functions of 
these proteins. 
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5 CONCLUSIONS AND GENERAL DISCUSSION 
1. SOCS proteins exert an E3-ligase activity toward cytokine and growth factor 
receptors. 
In this thesis, we characterized the ubiquitin ligase activity of SOCS2 and SOCS6. 
Both SOCS2 and SOCS6 were demonstrated to interact with Elongin B and C, cullin5 
and Rbx2 assembling a canonical ECS (Elongin/Cullin/SOCS) complex and they exert 
E3-ligase activity towards GHR and cKIT proteins, respectively. The E3-ligase activity 
results in degradation of these receptor and reduction in the cellular sensitivity toward 
GH and SCF. We have also displayed the importance of SH2 domains of both SOCSs 
in the binding to their target substrate. However, single point mutation in the SH2 
domain did not completely abolish the binding of SOCS6 to cKIT or SOCS2 to GHR 
suggesting that additional binding sites exist outside the SH2 domain that contribute to 
substrate recognition. This may provide SOCS proteins with a broader flexibility for 
targets recognition and hence widens their ability to regulate various signalling 
pathways. The physiological implication of this hypothesis is illustrated by the ability 
of SOCS2 of modulate GHR and TLR4 signalling, modulating the physiological 
response to high fat feeding.  
 
2. SOCS2 is in control of hepatic metabolism in conditions of dietary stress. 
We observed that SOCS2-/- mice on a high fat diet exhibit higher fat deposition in 
adipose tissue and skeletal muscle. This indicates a shift in fat mobilization to 
peripheral tissues in these mice. This effect could be a consequence of higher GH 
sensitivity, which results in a low plasma GH/IGF1 ratio. In this context, reduced 
circulating GH levels would cause a reduction in adipose tissue lipolysis and muscle 
lipid oxidation that cannot be compensated by the increase in GHR activity derived 
from SOCS2 deletion. In contrast, the increased hepatic GH sensitivity in SOCS2-/- 
mice results in enhanced VLDL secretion. The overall effect is a reduction of TAG 
accumulation in the liver; protecting mice from HFD induced steatosis. This model of 
control of lipid metabolisms would implicate that certain tissue such as muscle and 
fat may be less sensitive to SOCS2 inactivation. In other words, it seems that in 
muscle and adipose tissue, GH actions are primarily determined by its serum levels 
while GH liver actions can be modulated to a larger extent by SOCS2 regulation of 
GHR responsiveness. In support of this hypothesis is data showing comparatively 
higher expression of SOC2 mRNA in liver than in adipose tissue and muscle 268.  
 
Interestingly, the low hepatic steatosis was associated with significantly higher 
systemic insulin resistance indicated by both glucose and insulin tolerance tests. This 
was also associated with local insulin resistance observed in adipose (not published), 
skeletal muscle and the liver. It is possible therefore, that the observed insulin 
resistance in SOCS2-/-mice may result from the diabetogenic effect of enhanced GH 
actions in liver, alone or in combination with the proinflammatory pathways that are 
enhanced after SOCS2 deletion. We detected higher phagocytic activity and higher 
LPS-induced NF-kB activity in macrophages isolated from SOCS2, implying a role 
for SOCS2 in the regulation TLR4 signaling. No exogenous GH was added in this in 
vitro assays, suggesting that other SOCS2 targets than the GHR exist in the TLR4 
signaling pathway. On the other hand, GH is a component of the fetal bovine sera 
used to culture the cells and we cannot exclude paracrine production of GH by bone 
marrow derived macrophages. It is still possible that increased GH receptor content or 
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activity in macrophages of SOCS2-/- mice may crosstalk with TLR4 activated 
signaling pathways to enhance cytokine production. This is certainly a possibility in 
vivo and further experimentd in SOCS2-/- mice are warranted to ascertain the possible 
role of GH in the immunoregulatory actions of SOCS2224.   
  
3. The growth hormone-SOCS2 axis is perturbed by LXR ligands. 
SOCS are cytokine inducible proteins with a short half-life and their activity depends 
on their transcriptional activation. Therefore, SOCS actions can be altered by 
signaling factors regulating gene transcription. In the case of SOCS2, factors that 
modulate the GH activation of STAT5b would modulate SOCS2 function. We have 
demonstrated that LXR and SREBP1 significantly downregulates growth hormone 
signaling by targeting the STAT5b activity in hepatocytes resulting in reduced 
SOCS2 expression. A similar effect has been observed in macrophages where LXR 
activation interfere with LPS induction of SOCS3 and SOCS1 expression 269. 
However, It is unclear how SOCS2 is regulated in macrophages by LXR activation 
and if STAT5 downregulation may contribute to the known anti-inflammatory actions 
of LXR agonist in this tissue. It is worth noting that GM-CSF utilizes the 
JAK2/STAT5 signal transduction pathway and it is therefore possible that LXR may 
modulate macrophage differentiation triggered by this factor 270.  
 
An altered sensitivity towards hormonal/cytokine signals is a common disease 
causing mechanism, best exemplified by the insulin resistance associated to type 2 
diabetes. It will be interesting to learn how the SOCS system relates to insensitivity 
syndromes towards GH or pro-inflammatory cytokines in patients. In the case of GH, 
an inactivating mutation in the SOCS2 gene has been recently found in a human 
patient 220. In line with our findings in the SOCS2-/- mice, this patient exhibits an 
increased GH sensitivity defined by low GH and high IGF-1. A similar pattern of GH 
and IGF-1 is observed in obese patients 271 suggesting that SOCS2 downregulation 
may contribute to obesity. Genetic association studies have identified polymorphisms 
in SOCS2 that influence postnatal growth rate 219. It will be interesting to observe 
whether these individuals exhibit increased sensitivity to develop metabolic disorders 
with increased food intake and if those with metabolic syndrome will exhibit less 
NAFLD. It is yet an open question if there are pathological situations where the 
SOCS2 system is activated to reduce GH sensitivity. GH insensitivity is found in 
patients with GHR mutations but also after treatment with glucocorticoids, estrogen 
or androgens which induce SOCS2 expression 223, 272. GH resistance is also associated 
with kidney disorders 273 and certain metabolic conditions 274 where the role of 
SOCS2 deserves further studies.  It will be interesting to identify subpopulation of 
patients with unique disease features that can be attributed to SOCS protein actions. 
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6 FUTURE PERSPECTIVES 
The findings in this thesis increase our knowledge about the SOCS2 and SOCS6 
mechanism of action and of the physiological role of these proteins.  This in turn has 
generated novel questions for further studies to gain a better understanding of how 
SOCS proteins control metabolism and their role in the pathogenesis of other human 
diseases. 
 
Ø Our study suggests an anti-inflammatory role of SOCS2 through its regulation 
of TLR4 signaling. Further investigations are needed to define the signaling 
molecules within the TLR4 pathway that are targeted by SOCS2 and the 
possible role of GH signaling in this process.  
 
Ø Further studies are needed to understand the contribution of GH signaling to 
the SOCS2-/- reactivity to high fat diet. One possible approach is to cross 
breed the SOCS2-/- mice with GH deficient mice in order to understand GH-
independent functions of SOCS2. An alternative approach is to use systemic 
treatment with GH or GH receptor antagonist in order to reverse or enhance 
the effects observed in SOCS2-/- mice. 
 
Ø High fat diet induces hepatic inflammation and insulin resistance in SOCS2 
knockout mice. Therefore, we need to further investigate whether there is a 
causal relationship between inflammation and the development of insulin 
resistance.  Experiments that involve Kupffer cell ablation in SOCS2-/- mice 
and its substitution by SOCS2 WT macrophages will create chimeric mice 
where the role of hepatic inflammation can be studied. Other approaches may 
include systemic treatment of SOCS2-/- mice with NFκB inhibitors.  
 
Ø Our structural models of SOCS6-KIT binding have revealed some of the 
structural elements involved in substrate recognition. It will be very 
interesting to obtain similar data for the interaction between SOCS6 and the 
p85 regulatory subunit of the PI3 kinase complex. This would allow an 
increased understanding of how a single SOCS protein interacts with different 
substrates. Likewise, a complete understanding of SOCS2 actions on the GH 
receptor would require structural information regarding their interaction.  
 
Ø Recently a missense mutation in the SOCS2 gene has been identified in 
human. Other genome wide associated studies have identified polymorphisms 
in the vicinity of SOCS2 that are related to increased longitudinal growth. The 
knowledge accumulated in these studies using mice models may help to 
interpret the phenotype of these subjects and contribute to their clinical 
management. 
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